Next Article in Journal
A Thermostable Type I Collagen from Swim Bladder of Silver Carp (Hypophthalmichthys molitrix)
Next Article in Special Issue
Generation of Bioactive Peptides from Porphyridium sp. and Assessment of Their Potential for Use in the Prevention of Hypertension, Inflammation and Pain
Previous Article in Journal
Evaluation of Phytochemical Screening, Pigment Content, In Vitro Antioxidant, Antibacterial Potential and GC-MS Metabolite Profiling of Green Seaweed Caulerpa racemosa
Previous Article in Special Issue
Enzyme Inhibitors from Gorgonians and Soft Corals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 21
Issue 5
10.3390/md21050279
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Marine Invertebrates: A Promissory Still Unexplored Source of Inhibitors of Biomedically Relevant Metallo Aminopeptidases Belonging to the M1 and M17 Families

by
Isel Pascual Alonso
1,*,
Fabiola Almeida García
1,
Mario Ernesto Valdés Tresanco
1,2,
Yarini Arrebola Sánchez
1,
Daniel Ojeda del Sol
1,
Belinda Sánchez Ramírez
3,
Isabelle Florent
4,
Marjorie Schmitt
5 and
Francesc Xavier Avilés
6,*
1
Center for Protein Studies, Faculty of Biology, University of Havana, Havana 10400, Cuba
2
Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada
3
Centro de Inmunología Molecular, Habana 11600, Cuba
4
Unité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR7245), Muséum National d’Histoire Naturelle, CNRS, CP52, 57 Rue Cuvier, 75005 Paris, France
5
Université de Haute-Alsace, Université de Strasbourg, CNRS, LIMA UMR 7042, 68000 Mulhouse, France
6
Institute for Biotechnology and Biomedicine and Department of Biochemistry, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2023, 21(5), 279; https://doi.org/10.3390/md21050279
Submission received: 27 March 2023 / Revised: 25 April 2023 / Accepted: 26 April 2023 / Published: 28 April 2023
(This article belongs to the Special Issue Enzyme Inhibitors from Marine Resources)
Browse Figures
Versions Notes

Abstract

:
Proteolytic enzymes, also known as peptidases, are critical in all living organisms. Peptidases control the cleavage, activation, turnover, and synthesis of proteins and regulate many biochemical and physiological processes. They are also involved in several pathophysiological processes. Among peptidases, aminopeptidases catalyze the cleavage of the N-terminal amino acids of proteins or peptide substrates. They are distributed in many phyla and play critical roles in physiology and pathophysiology. Many of them are metallopeptidases belonging to the M1 and M17 families, among others. Some, such as M1 aminopeptidases N and A, thyrotropin-releasing hormone-degrading ectoenzyme, and M17 leucyl aminopeptidase, are targets for the development of therapeutic agents for human diseases, including cancer, hypertension, central nervous system disorders, inflammation, immune system disorders, skin pathologies, and infectious diseases, such as malaria. The relevance of aminopeptidases has driven the search and identification of potent and selective inhibitors as major tools to control proteolysis with an impact in biochemistry, biotechnology, and biomedicine. The present contribution focuses on marine invertebrate biodiversity as an important and promising source of inhibitors of metalloaminopeptidases from M1 and M17 families, with foreseen biomedical applications in human diseases. The results reviewed in the present contribution support and encourage further studies with inhibitors isolated from marine invertebrates in different biomedical models associated with the activity of these families of exopeptidases.

Graphical Abstract

1. Introduction

Proteolytic enzymes, known as peptidases or proteases, are critical in all living organisms [1]. Proteases can act as exo- and/or endopeptidases. They are segregated in classes that strongly depend on the chemical nature of the groups involved in catalysis. The recognized mechanistic classes are aspartic, cysteine, glutamic, metallo, asparagine, mixed, serine, threonine, and a group dedicated to unknown catalytic type [1].
Peptidases are one of the most abundant groups of enzymes in living organisms. Thus, in mammals, more than six hundred genes have been assigned to them. They control the activation, synthesis, and turnover of proteins and regulate most biochemical and physiological processes, such as digestion, fertilization, growth, differentiation, cell signaling/migration, immunological defense, wound healing, and apoptosis [1,2,3]. They are consequently major regulators of homeostasis, ageing, and different human diseases such as cancer, hypertension, diabetes, inflammation, neurodegeneration, and Alzheimer’s disease, among others [4,5,6]. Proteases are also essential for the propagation of infectious agents, being major contributors of pathogenesis in several infectious diseases, including the current coronavirus emergent pandemic SARS COVID-19 [1,7,8,9,10,11,12,13,14].
Among peptidases, aminopeptidases catalyze the cleavage of the N-terminal amino acids of proteins or peptide substrates. They are distributed in many phyla and play critical roles in physiology and pathophysiology [1,8,9,15]. In mammals, they have a widespread cellular distribution in various organs and are found within cells in many subcellular organelles, in the cytoplasm, as integral membrane proteins, or are exposed or secreted extracellularly [8,16,17,18]. They are mainly metallopeptidases belonging to different families such as M1 and M17, although cysteine and serine peptidases are also included in this group [1]. Among the best representatives of aminopeptidases that are currently in the focus of biomedical investigation, we can pinpoint the M1 family neutral aminopeptidase (APN, EC 3.4.11.2), glutamyl aminopeptidase (APA EC 3.4.11.7) and thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE; EC 3.4.19.6), and M17 neutral aminopeptidase, also known as leucyl aminopeptidase (LAP, EC 3.4.11.21) (Figure 1). These enzymes are involved in multiple physiological processes as well as in cancer, hypertension, central nervous system disorders, inflammation, immune system disorders, skin pathologies, and infectious diseases, such as malaria, and are current targets for the development of new therapeutic drugs [8,9,19].
Marine habitats are an extraordinary source of structurally complex bioactive metabolites, characterized by unique functions with marked biological activities and polished through evolution. These features can be attributed to varied environmental conditions, such as access to/lack of light, high pressure, aqueous environment, ionic concentration, pH and temperature changes, scarcity of nutrients, and restricted living spaces. Marine organisms are an abundant source of bioactive molecules (including saccharides, polysaccharides, peptides, proteins, polyketides, polyphenolic compounds, sterol-like products, alkaloids, quinones, and quinolones, among others), such as toxins [20,21], antimicrobial peptides [22,23], antiviral compounds [24], enzymes and enzyme inhibitors [25,26,27,28], and particularly peptidases [29,30] and peptidase inhibitors of almost all mechanistic classes [31,32,33,34,35,36,37,38,39,40,41,42]. These bioactive molecules have a great diversity of chemical structures, high potency, and diverse specificities, especially the inhibitors of metalloenzymes (Figure 2, Figure 3 and Figure 4) [37,43,44,45,46,47,48,49,50,51,52,53,54]. These inhibitory biomolecules are frequently involved in nutrition, homeostasis, reproduction, and communication of marine organisms [27]. Additionally, the high concentration of coexisting organisms in a limited area also makes them very competitive and complex, resulting in the development of adaptations and behaviors aimed at safeguarding the species. Since most invertebrates (e.g., sponges, bryozoans, tunicates, cnidarians, and mollusca snails, among others) lack morphological defense structures, peptidase inhibitors are also part of mechanisms related with protection against predators, infection, and competition [55]. In the present contribution, we review and summarize the status of metalloaminopeptidase inhibitors isolated from marine organisms with a focus on the M1 and M17 families of enzymes targeted in biomedical studies.

2. M1 and M17 Metalloexopeptidase Inhibitors Isolated from Marine Invertebrates

2.1. Metallopeptidases: General Characteristics and Classification

Metallopeptidases constitute the most diverse catalytic type within proteases, since they include both endopeptidases and exopeptidases, cytosolic enzymes, and others that are secreted to the outside of cells, as well as enzymes associated with the plasma membrane and cell organelles. They are widely distributed in all forms of life such as viruses, bacteria, fungi, and plant and animal cells, indicating the important role they play in biological processes.
Metalloproteases are included among the hydrolases in which the nucleophilic attack on the peptide bond is mediated by a water molecule. This is a feature they share with aspartic-type peptidases, but in metallopeptidases, a divalent metal cation activates the water molecule [63]. This divalent cation is usually zinc (Zn2+) but can sometimes be cobalt (Co2+) or manganese (Mn2+). The metal ion is held in the protein structure by amino acids that act as ligands.
Metallopeptidases can be divided into two large groups based on the number of metal ions required for catalysis. In many metallopeptidases, only one metal ion is required, which frequently is Zn2+; however, there is another group of families in which two cocatalytically acting metal ions are required. Within this group, there are families that have two Zn2+ ions and all the families in which Co2+ or Mn2+ are essential for catalysis. In families where only one metal ion acts, three amino acid residues are required to act as metal ligand coordinators, and in families with cocatalytic ions, only five amino acids are required since one of them acts as a ligand coordinator for both metal ions. All metallopeptidases with cocatalytic ions are exopeptidases, while metallopeptidases with a single metal ion can be both exo- and endopeptidases.
Various attempts have been made to classify proteases. The most accepted today is the one initially proposed by Rawlings and Barrett [64,65] that is continuously updated at (https://www.ebi.ac.uk/merops/, accessed on 9 January 2023) [1]. From the general classification of the nine mechanistic classes, they first group the enzymes of each class into families. A family is defined as a group of (homologous) peptidases in which each member shows significant amino acid sequence identity with the “type enzyme” or at least with another member of the family homologous to the type enzyme, mainly in the region of the peptidase that is related to its catalytic activity. The selection criteria used by these authors were very strict, in such a way that they guarantee a common ancestor for the members of a family, which are, therefore, homologous according to the definition of Reeck et al. [66]. Each family is named with a letter denoting the catalytic type (Example: M for metallopeptidases), followed by an arbitrarily assigned number. At a higher level of hierarchy, we find the clan, which is the term used by these authors to describe a group of families, whose members originate from a common ancestor protein but which have diverged to a point where relationships between them cannot be demonstrated by homology in their primary structures. The main evidence for the clan level is the relationship between families in terms of similarities in the three-dimensional structure of their members, in the arrangement of catalytic residues in the peptide structure, as well as similarities in the amino acid sequence around the catalytic residues [1].
Up to now, 16 clans of metallopeptidases have been described: MA, MC, MD, ME, MF, MG, MH, MJ, MM, MN, MO, MP, MQ, MS, MT, and MU, with six of them comprising exo-peptidases. Overall, they form 76 families, with clans MA and MF being two of the most well characterized with enzymes from all living organisms [1].

2.2. Clan MA: Subclan MA (E)

The clan MA is the largest of the metallopeptidases, with a total of 49 families [1], all consisting of enzymes that contain a single Zn2+ in their active sites. This clan is made up of both endopeptidases and exopeptidases, comprising aminopeptidases (families M1, M2, M4, M5, M9, M13, M30, M36, M48, and M61), carboxypeptidases (M2 and M32), peptidyl-dipeptidases (M2), oligopeptidases (M3 and M13), and endopeptidases (families M4, M10, and M12). In the enzymes of the MA clan, the Zn2+ atom is coordinated to the protein through two His residues, which are part of the HEXXH motif. In addition to the His residues, the catalytic Zn2+ is coordinated by a water molecule and a third residue, the nature of which determines the clan’s subdivision into the MA (E) and MA (M) subclans. In the subclan MA (M), the third ligand can be a residue of His or Asp within the HEXXHXXGXXH/D signature sequence, while in subclan MA (E) the third ligand is a residue of Glu, located at least 14 residues after the carboxyl terminus of the HEXXH motif [1] (Figure 5). The oxygen atom of the water molecule that acts as a metal ligand is the nucleophilic agent that attacks the carbonyl of the peptide bond to be hydrolyzed.
Thermolysin (EC 3.4.24.27), a secretory endopeptidase, is the model enzyme of the MA clan and its structure, widely characterized, is a point of reference for the study of the enzymes of this clan due to the high structural similarity between them in terms of the organization of the active center [1]. Among the most studied families of the subclan MA (E) is M1, whose members show a wide distribution in the living world (Table 1); furthermore, they are involved in many functions that include cell maintenance, growth, development, and defense [8]. This family includes enzymes of Gram (+) and Gram (−) bacteria, cyanobacteria, archaea, protozoa, fungi, animals, and plants [1,8].

2.3. M1 Family of Metalloaminopeptidases

The aminopeptidases of the M1 family exist in monomeric or dimeric forms. In eukaryotes, they are generally membrane-associated enzymes such as mammalian APN (i.e., from human or pig), acidic or glutamyl aminopeptidase (APA), adipocyte-derived leucine aminopeptidase, and thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE), also known as pyroglutamyl peptidase II [16]. Some are cytosolic enzymes, such as leukotriene A4 hydrolase (bifunctional enzyme with aminopeptidase activity) [67] and aminopeptidase B (APB) [68], or associated with the cell wall [9], such as the neutral aminopeptidase (APN, EC 3.4.11.2) of the yeast Candida albicans [69]. The structure of the membrane-bound aminopeptidases of the M1 family, in general, comprises a short intracellular tail attached to the transmembrane domain and a large ectodomain formed, in turn, by 2- or 3-folded and conserved domains. Domain I, N-terminal, has a β-sheet nucleus that, although it is widely exposed to the solvent, contains a hydrophobic region that continues in an anchorage region in the membrane. Catalytic domain II, such as that of thermolysin, contains an active site flanked by a mixed structure of β-sheet and α-helix that is highly conserved throughout the family. Domain III, which is composed of an immunoglobulin-like fold, does not appear in some family members (such as leukotriene A4 hydrolase). Domain IV, C-terminal, is the most variable region within the family. It is completely helical, with such an arrangement that it covers the active site; it is also involved in the dimerization of the mammalian isoforms [8]. Disulfide bridges and abundant glycosylations are generally seen in this extracellular region, and some of these enzymes are surface antigens [1,16].
In the M1 family, a well-conserved motif is the Gly-Ala/X-Met-Glu-Asn (GAMEN/GXMEN) sequence. This sequence, also known as the exopeptidase motif, frequently shows variations in the first two residues, and is very useful for the identification of family members [8,16,70] (Figure 5).
Through the technique of crystallography and X-ray diffraction, the three-dimensional structures of several members of this family have been elucidated, such as leukotriene A4 hydrolase in complex with its inhibitor bestatin [71]; tricorn-interacting factor 3 of Thermoplasma acidophilum [72]; Escherichia coli APN (Pep N) in complex with its inhibitor bestatin [73]; Plasmodium falciparum (PfA-M1) alone and in complex with bestatin and low molecular mass analogs [74,75,76]; human APA [77]; human ERAP-1 [78]; and porcine and human APN in complex with substrates and bestatin [70,79], among others (Table 2) (Figure 6). In all these structures, it can be seen that the catalytic domain of this enzymatic family presents a high structural similarity with thermolysin, despite the fact that in some cases, there is only 7% identity in sequence with the corresponding polypeptide chains [71]. The high availability of M1 aminopeptidase structures, the well-studied active site able to the binding of small molecules, and the well characterized reaction mechanisms, make M1 aminopeptidases ideal candidates for the application of structure-guided inhibitor discovery, including high-throughput screenings in different databases of marine and other natural compounds. These inhibitors have potentialities in different infectious and chronic human diseases [80,81].

2.4. Inhibitors of M1 Family Isolated from Marine Invertebrates

2.4.1. A Specific Inhibitor of Thyrotropin-Releasing Hormone-Degrading Ectoenzyme/Pyroglutamyl Aminopeptidase II Isolated from a Marine Organism

Thyrotropin-releasing hormone (TRH), an N-terminal blocked tripeptide (pGlu-His-ProNH2), is mainly produced by brain neurons. Expressed by neurons of the paraventricular nucleus of the hypothalamus, TRH is a hypophysiotropic factor that increases the synthesis and release of thyroid stimulating hormone (TSH) and prolactin (PRL) from the adenohypophysis. In other central nervous system (CNS) circuits, it functions as a neurotransmitter and/or neuromodulator [82]. This peptide has therapeutic properties in the treatment of brain and spinal damage and various neurodegenerative disorders [83]. However, TRH effects are of short duration, in part because the peptide is hydrolyzed in blood and extracellular space by TRH-DE, the thyrotropin-releasing hormone-degrading ectoenzyme, a M1 family metallopeptidase. TRH-DE is enriched in various brain regions but is also expressed in peripheral tissues including the anterior pituitary and the liver, which secretes a soluble form into blood. Among the M1 metallopeptidases, TRH-DE is the only member with a very narrow specificity, hydrolyzing preferentially the pGlu-His bond of TRH, its best characterized biological substrate, making it a target for the specific manipulation of TRH activity. TRH-DE presents an anatomical location that correlates partially with TRH receptors in various regions and is very strictly regulated by different hormones and hypothalamic factors, as well as by various pharmacological and pathophysiological conditions that alter the transmission of TRH-mediated signals. The regulation of TRH-DE activity may be very important for the adjustment of communication mediated by this peptide [84]. Therefore, TRH-DE inhibitors are important tools for studying the physiological functions of this enzyme and TRH in the CNS, as well as for enhancing the different actions of TRH by protecting the degradation of endogenous TRH or exogenously administered analogues [85]. TRH-DE inhibition may be used to enhance TRH activity in different pathologies (Figure 7). Only a few synthetic PPII inhibitors have been described [86,87,88].
A joint project of the Faculty of Biology, University of Havana, Cuba, with the Institute of Biotechnology of UNAM, Mexico, involving a screening in aqueous extracts from 26 Cuban coastline marine organisms (Table 3) resulted in the first natural inhibitor of TRH-DE identified and isolated from the marine annelid Hermodice carunculata (Figure 8); it was named HcPI. As a result of this screening, we also detected inhibitory activities of porcine kidney cortex dipeptidyl peptidase IV in the species Phallusia nigra, Mycale microsigmatosa, Condylactis gigantea, Stichodactyla helianthus, and Palythoa caribbaeroum. HcPI is a 580 Da compound (molecular mass determined by ESI-TOF mass spectrometry), with a possible polymeric structure and the presence of bromine in its structure, as well as amide-type bonds. HcPI potently inhibits TRH-DE with a Ki value of 70.3 nmol/L in a slow and reversible way, making it one of the most powerful inhibitors described against this enzyme [49] (Figure 9A).
Inhibitory specificity studies carried out against proteases of all mechanistic classes indicate that HcPI is highly specific for TRH-DE. The specificity of the inhibitory activity was assayed using several enzymes from each mechanistic class of proteinases. In a concentration range from 33 to 660 ng/mL and preincubation times at 37 °C of 5, 10, or 30 min, HcPI was not active against serine (trypsin, chymotrypsin, elastase, and DPP-IV), cysteine (papain, bromelain, and PPI), or aspartic (pepsin and PR-HIV) proteases nor against metalloproteinases (collagenase, gelatinase, ACE, aminopeptidase N, and carboxypeptidase A). It was further confirmed that HcPI inhibits, in vitro, thyroliberinase, a soluble version of TRH-DE that inactivates TRH in the bloodstream. The inhibition is dose-dependent, with a Ki value of 51 nmol/L, similar to that previously described for TRH-DE. The specificity results support the idea that HcPI should be useful to study the role of TRH-DE in different experimental models. HcPI is not toxic in vivo and its intraperitoneal injection in BalbC mice decreases TRH-DE activity in the pituitary and in different brain regions such as the hypothalamus, cerebellum, and olfactory bulb [49] (Figure 9C). The inhibition of TRH-DE in vivo in this experimental model causes a transient increase in the serum concentrations of prolactin (PRL) and thyrotropin (TSH), which indicates an in vivo enhancement of the actions of endogenous TRH when degradation by TRH-DE is decreased. Additionally, studies on cells were performed. First, in primary cultures of adenohypophyseal cells, 45 min of incubation with HcPI produces a decrease in the activity of membrane-associated TRH-DE, highly dependent on the dose of inhibitor tested with an IC50 of 8.3 µg/mL (Figure 9B). Incubation with 8 µg HcPI/mL decreases enzyme activity by 42% from 5 min, an effect stable for at least one hour. Once enzyme inhibition was demonstrated in cultures, the effect of the enzyme on TRH-mediated communication was evaluated, and it was detected that in the absence of TRH in the system, the presence of HcPI (50 µg/mL) does not change the basal levels of secretion of TSH, or PRL. On the other hand, in the presence of TRH (10 nmol/L), the inhibition of TRH-DE by HcPI caused an increase in the levels of PRL released after 30 min by lactotrophs, specialized cells of the adenohypophysis. These results were confirmed in parallel by inhibition of TRH-DE synthesis with the use of antisense RNA, which demonstrated for the first time in a direct way the effects of the regulation of PPII activity on one of the functions of TRH [89]. Intraperitoneal injection of HcPI (1, 5, 20, or 50 µg/g) in mice did not induce any mortality, obvious motor effect, or weight change for up to 15 days. The effect of different doses of HcPI injected intraperitoneally was tested on mouse PPII specific activity. Compared to saline injected animals, PPII activity was significantly decreased 45 min after injection in most of the tissues analyzed; the effect was dose-dependent. Less than 1 mg of the inhibitor per g of animal weight was sufficient to decrease activity by more than 50% in hypophysis; the maximum dose used (5 µg/g) almost completely abolished the activity. The order of potency was as follows: hypophysis > hypothalamus > cerebellum > olfactory bulb (Figure 9) [49]. Other experiments related to the role of PPII in TRH communication within the hypothalamic–adenohypophysis–thyroid axis were continued with the use of animal models. In these studies, HcPI was injected at the beginning of the experiment at a dose of 50 µg/g of animal weight to Wistar rats, dissolved in physiological saline (doses of 5–10 µg/g of animal weight strongly reduce PPII activity in the adenohypophysis and decrease it in CNS regions). The controls received only saline. Four groups of animals were subsequently treated with 1 ng/g animal weight TRH in saline or saline only and slaughtered by decapitation 15 min after the second treatment. Two additional groups were transferred to a cold room kept at 4 °C for 30 min and similarly sacrificed after the end of the experiment. Since cold stress rapidly activates the hypothalamic–adenohypophysis–thyroid axis by increasing concentrations of TRH in the portal hypothalamus–pituitary vessels, this paradigm was used in addition to exogenous administration of TRH, with the objective of evaluating the effects of inhibition of TRH-DE by HcPI on a naturally occurring surge of circulating TSH concentration. Compared to animals that received a single injection of saline, TRH-DE activity is significantly decreased in the hypothalamus and in the pituitary of animals that receive a single dose of HcPI. Similar changes are observed in the activity of serum thyroliberinase. Inhibition of TRH-DE activity by HcPI has no effect on baseline TSH levels, as observed in primary adenohypophyseal cell cultures. However, in animals injected with exogenous TRH or exposed to ambient cold, inhibition of TRH-DE activity by HcPI is associated with a significant increase in serum TSH concentration when compared to control groups that only received saline (Sánchez-Jaramillo et al. 2009). These results demonstrated for the first time the role that TRH-DE exerts on TRH activity and TSH secretion by adenohypophysis and made HcPI a very useful tool for further studies and potential biomedical applications in diseases such as Non-Thyroidal Illness Syndrome (NTIS) in which the levels of thyroid hormones are reduced [90].

2.4.2. Inhibitors of Aminopeptidase N Isolated from Marine Organisms

Neutral aminopeptidases are enzymes that catalyze the cleavage of neutral amino acids from the N-terminus of protein or peptide substrates. They have been classified in several metallopeptidase families, such M1 and M17 [1,8,9]. These enzymes are present in all living organisms, but the diversity of the functions in which they are involved is far from being entirely deciphered. Mammalian neutral aminopeptidase (APN, EC 3.4.11.2, M1 family) is the most extensively studied member of the M1 family of zinc-dependent aminopeptidases; it is noteworthy that it catalyzes the cleavage of not only neutral but also basic N-terminal residues. This enzyme, also known as CD13, is widely expressed on cell surfaces of tissues, such as intestinal epithelia and the nervous system. Mammalian APN is a type II membrane protein generally found as a homodimer in several mammalian species. Full-length human APN consists of 967 amino acids with a short N-terminal cytoplasmic domain, a single transmembrane segment, and a large ectodomain containing two catalytic motifs highly conserved across the M1 family: the zinc-binding motif HEXXHX18E and the exopeptidase signature GAMEN [70]. APN plays pivotal roles in many physiological processes, such as pain sensation, sperm motility, cell–cell adhesion, and blood pressure regulation (Figure 10) [8,18]. This enzyme is also up-regulated in human pathologies, such as coronavirus entry, inflammation, immune cell chemotaxis, tumor angiogenesis, and metastasis in several types of cancer, with a strong correlation between the level of APN expression of a cell and its resultant invasive capacity (Figure 10). Dysregulation of APN expression evolves in almost all types of human malignancies, including breast cancer, cervical cancer, ovarian cancer, prostate cancer, non-small-cell lung cancer (NSCLC), liver cancer, colon cancer, cirrhosis gastric cancer, pancreatic cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (SCC), melanoma, osteosarcoma, and thyroid cancer [19,91]. This makes human APN an attractive target for the treatment of diseases, including cancers (Figure 11) [8,18,19,91,92,93]. Accordingly, strategies for its inhibition have been developed primarily for the treatment of pain [94,95]. Only Ubenimex (bestatin), a drug inhibitor, is currently approved by the FDA for its uses in human pathologies, mainly in cancer [91].
Natural inhibitors of human and mammalian APN in general are scarce and have mainly been described from microorganisms [18,96], plants [97], marine invertebrates [36,48,98,99], and more recently from Cuban toad secretions [100,101] (Figure 12). Several compounds from marine organisms have been described with anticancer activities; however, very few of them have been linked with APN inhibition or interaction [102,103,104,105,106]. In the next section, we review the information available regarding marine invertebrates as a promissory and still unexplored source of inhibitors of APN with biomedical relevance mainly in cancer.

Psammaplin A

Psammaplin A (PsA) is a natural bromothyrosine compound belonging to the open-chain-oximinoamidesis bromo-derivates group (Figure 13), isolated from the association between two sponges, Poecillastra sp. and Jaspis sp. [107], which represents the first isolated natural product containing oxime and disulfide moieties from marine sponges. Subsequently, other natural derivatives, such as biprasin, psammaplin C, psammaplin E, psammaplin F, psammaplin G, and psammaplin K (Figure 13), were also isolated and described [108,109,110,111,112].
Several biological activities have been described for PsA; it is an antibacterial mainly against Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) due to DNA gyrase inhibition and bacterial DNA synthesis arrest [113]. PsA also inhibits chitinases that are common in fungi and are crucial for the control of ecdysis in insects [114]. In mammalian cells, PsA inhibits topoisomerase II, an enzyme catalyzing DNA relaxation, with a high IC50 of 18.8 mM [114]. In 2004, almost at the same time our group described HcPI as an inhibitor of TRH-DE, Shim et al. [48] found that PsA inhibits mammalian APN with a Ki value of 15 µM in a non-competitive way. Structural analogues of PsA, in which phenolic hydroxyl groups were replaced, did not inhibit human or porcine APN, indicating that these groups are crucial in the recognition and inhibition of this enzyme in mammals. This finding perfectly agreed with the effectiveness of bulky and hydrophobic groups in molecules targeting APN [115]. However, no other in-depth structure–activity or docking studies of aminopeptidase N inhibition by PsA have been carried out.
Psammaplin A possesses antiproliferative activities against various cancer cell lines, including triple-negative breast (TNBC, MDA-MB-231), doxorubicin-resistant human breast (MCF-7/adr), colon (HCT15), ovarian (SK-OV-3), lung (A549, LM4175), bone (BoM1833), skin (SK-MEL-2), central nervous system (BrM-2a, XF498) [116,117,118], and Ishikawa endometrial cells [119]. Some of the mechanisms described to explain the antiproliferative effects of this compound are the induction of cell cycle arrest and apoptosis associated with different factors [119,120]. Pretreatment with PsA was also shown to increase the sensitivity of human lung and glioblastoma cancer cells to radiation in vitro [120]. Moreover, this compound showed suppressive effects of the invasion and tube formation of endothelial cells stimulated by the basic fibroblast growth factor [48]. These results demonstrate that PsA is a new APN inhibitor that can be developed as a new antiangiogenic agent.
PsA has also been described as a histone deacetylase (HDAC) inhibitor [119,121]. The mechanism of action underlying the HDAC inhibitory effect of PsA involves a change in the redox state of the disulfide bond. Replacement of the sulfur atom leads to the formation of a mercaptan, which in turn chelates the Zn+ ion present in the characteristic active site of the HDAC enzyme, modifying its conformational state and thus preventing its accessibility to the natural substrate. This new conformational state determines an increase in acetylation levels of histone H3, a well-known epigenetic marker of chromatin structure and function, suggesting selectivity for HDACs. Moreover, PsA also exhibits potent enzyme inhibitory and antiproliferative activities under reduced conditions in cells, which indicates that PsA could be used as a natural prodrug [121].
Although PsA possesses a broad spectrum of bioactivities, its in-depth study has been hindered due to the limited amount of the compound that can be isolated from marine sources as well as its poor physiological stability. For these reasons, homodimeric or heterodimeric analogs of PsA have been obtained by chemical synthesis through a disulfide exchange strategy (Figure 14) [122]. Some of the new synthetic compounds, particularly heterodimeric derivatives, displayed higher antibacterial activity than psammaplin A, comparable to clinically used drugs vancomycin and ciprofloxacin [123,124]. However, the APN inhibitory activity of all the synthetic psammaplin derivatives (examples in Figure 13 and Figure 14) has not been evaluated, being a still unexplored source of new aminopeptidase N inhibitors with biomedical potentialities taking into account the promissory effects of these compounds on several biomedical models [122].

Identification of Inhibitory Activity of Mammalian APN in Marine Invertebrates from Cuban Coastline

Considering the identification of a highly specific inhibitor of TRH-DE in the marine annelide Hermodice carunculata in aqueous extracts from Cuban marine invertebrates, our group extended the screening to porcine and human APN as targets. As part of a first study carried out in 2011–2015 in aqueous extracts from marine invertebrates belonging to the phyla (Table 4), an APN inhibitory activity is detected in all the extracts evaluated except for Lebrunia danae and Hermodice carunculata, whose extracts display values of enzymatic activity higher than those of the control test of porcine APN (pAPN) (Table 4, Figure 15). The L-Leu-pNA substrate is also hydrolyzed when the assay is performed only in the presence of the extract and activity buffer, indicating the possible presence of a neutral aminopeptidase type activity in these two species. The extracts of the species Bryozoo sp. 2, Diplosoma listerianum, Lisoclinum verrilli, Eucidaris tribuloides, and Ophiocoma echinata were selected as the most promising in terms of the specific inhibitory activity of porcine APN as well as a dose-dependent inhibition behavior [125]. The extracts of the Phallusia nigra, Ascidia sidneyense, Microcosmus guanus, Steinacidia turbinata, and Poticlenum constellatum species do not show inhibition at increasing concentrations, indicating that the initial result is probably due to a component of the extract that interferes with the correct determination of the enzyme activity. All the selected extracts, except that of Lisoclinum verrilli, show slow inhibition, in the order of minutes. On the other hand, for the latter, equilibrium is reached within 1 min of preincubation time, suggesting a fast interaction of the inhibitory components of the extract with the porcine APN. The IC50 values are in the range of 0.11–2.39 mg/mL (Table 4), with the highest efficiency being for the extracts of the two sea squirts (Diplosoma listerianum and Lisoclinum verrilli) and that of Bryiozoo sp2. The active extracts were submitted to clarification treatments (such as 2.5% trichloroacetic acid and heat treatments) to eliminate contaminants (mainly proteins) and to promote dissociation from endogenous inhibitor–target complexes. Clarification increases the specific inhibitory activity of the extracts, suggesting that the procedure should be useful in future works dealing with the isolation of the inhibitory molecules [98].
In a second study performed in 2015–2019, aqueous extracts from species belonging to the phyla Mollusca, Poriphera, Echinodermata, and Cnidaria (Figure 16) were screened using human placental APN as the target (Table 5). The initial evaluations allowed detection of an inhibitory activity of hAPN only from the species Cenchritis muricatus and Isostichopus badionotus. Increased L-Leu-AMC hydrolysis rates over the control value are found instead of inhibitory activities for the rest of the species. These results suggest either the presence of an activator of the target enzymes used in the assays or neutral aminopeptidase-like enzymes hydrolyzing L-Leu-AMC in the corresponding aqueous extracts. The clarification of all aqueous crude extracts (2.5% TCA treatment) increased, in all cases, the recovery of specific inhibitory activities as compared to their detection in positive crude extracts. The treatment also allowed the identification of inhibitory activities from species that were negative after screening using aqueous crude extracts. This result indicated that clarification eliminates contaminants and/or induces dissociation from endogenous inhibitor–target complexes that do not allow the detection of inhibitory components in crude extracts.
The clarified extracts (2.5% TCA) from the species Cenchritis muricatus, Nerita peloronta, Nerita versicolor, Lissodendoryx (Lissodendoryx) isodictyalis, Tripneustes ventricosus, Echinaster (Othilia) echinophorus, Isostichopus badionotus, Stichodactyla helianthus, Bunodosoma granuliferum, and Physalia physalis were used to continue the inhibition studies vs. human APN (hAPN) [98]. Additionally, the enhanced activities over the control detected in some extracts were lost, in all cases, after the 2.5% TCA treatments, suggesting susceptibility of the active molecules to the chaotropic agent and/or to the acidic pH of the molecule(s) responsible for these effects (Table 5).
To test the presence of neutral aminopeptidase-like enzymes in aqueous crude extracts, preliminary enzymatic assays were performed using different amounts of the samples (in absence of the initial target hAPN) in the presence of L-Leu-AMC. A linear dependence of the initial rate versus the amount of crude extract in the assays was detected for the species Nerita peloronta, Nerita versicolor, Lissodendoryx (Lissodendoryx) isodictyalis, Tripneustes ventricosus, Echinaster (Othilia) echinophorus, Stichodactyla helianthus, Bunodosoma granuliferum, and Physalia physalis. These neutral aminopeptidase-like activities were recently characterized by a kinetic approach combining substrates, inhibitors, and cations, showing for the first time a biochemical behavior indicative of the presence of M1 and M17 enzymes in these species [30].
The clarified extracts inhibit hAPN activity in a dose-dependent manner, and the inhibition was characterized by a concave behavior, indicating the reversibility of the inhibition and corroborating the presence of inhibitory molecules in the samples (and not artifacts interfering with the enzyme activity). The IC50 values are in the range of 11.7–567.6 µg/mL [98]. As a promissory result, hAPN is inhibited with IC50 values around or less than 100 µg/mL in four of the ten species tested (Lissodendoryx (Lissodendoryx) isodictyalis, Tripneustes ventricosus, Isostichopus badionotus, and Stichodactyla helianthus); this inhibition is stronger than that produced by bestatin or amastatin (pure compounds) assayed in parallel as controls (Table 5) [98].
Taking into account that the effect of the inhibition of hAPN was corroborated, the effect of each treated extract on the viability of two APN+ cancer cell lines PC3 and 3LL was evaluated [98]. All treated extracts, and bestatin used as a positive control, have a dose-dependent effect on PC3 and 3LL cell viability. The higher effects on both cell lines, with IC50 values below 100 µg/mL, are observed for the species showing the strongest hAPN inhibition. An IC50 value under 5 µg/mL for L. isodictyalis extract vs. both cancer cells lines, similar to the effect displayed by bestatin, indicates that this species is promissory for the isolation of hAPN inhibitors. In this work, the IC50 values for cell viability are in good agreement with the IC50 values for hAPN inhibition, including the bestatin results. To the best of our knowledge, this work was the first to show concomitantly natural inhibitor potency on hAPN and indications of activity on hAPN-expressing cells [98].

Inhibitors of Aminopeptidase A Isolated from Marine Organisms

Membrane glutamyl aminopeptidase, also known as acidic aminopeptidase (APA, EC 3.4.11.7), is a type II membrane protein of the M1 family, MA subclade (E), of metallopeptidases [8] (Figure 1B). This enzyme is widely distributed in mammalian tissues. Aminopeptidase A (APA) has been reported to have molecular weights around 109 kDa for the human and 108 kDa for the porcine enzyme [1]. APA’s S1 pocket accommodates acid residue side chains, whereby this enzyme hydrolyzes aspartic and glutamic residues from the peptide N-terminus [77]. APA performs fundamental functions in a wide range of physiological processes, since it participates in the metabolism of angiotensin II, involved in the renin–angiotensin system in the central nervous system and other anatomical locations, making it an important regulator of blood pressure (Figure 17) [126]. In addition, it is involved in the development of Alzheimer’s disease and glomerulosclerosis and in the progression of cancer. It is associated with the development of renal neoplasms, malignant trophoblasts, renal choriocarcinoma, and colorectal cancer [126,127,128,129,130]. APA plays a key role in blood pressure regulation, which has made it a promising therapeutic target for the development of antihypertensive agents (Figure 17) [30,126,131].
Recently, we extended the screening of marine organism extracts to porcine aminopeptidase A (pAPA). We observed that extracts from the species Nerita peloronta, Nerita versicolor, Lissodendoryx (Lissodendoryx) isodictyalis, Tripneustes ventricosus, Echinaster (Othilia) echinophorus, Isostichopus badionotus, and Stichodactyla helianthus displayed dose-dependent inhibition of porcine APA activity, with IC50 values in the range of 11.00–1005.00 µg/mL (Table 6), showing that Nerita versicolor has a certain selectivity for pAPA rather than for hAPN. These results strongly support the exploration of marine fauna of invertebrates as promissory sources of inhibitors of M1 family enzymes with potential biomedical applications, such as APN and APA.

2.5. Clan MF: Family M17

Clan MF contains aminopeptidases that require cocatalytic metal ions for activity. The clan contains only the single family M17, a family of leucyl aminopeptidases [1], summarized in Table 7. The M17 aminopeptidases utilize two divalent metal ion cofactors to catalyze the removal of selected N-terminal amino acids from short peptide chains. M17 aminopeptidases are found in all kingdoms (Figure 18), wherein they possess a characteristic homo-hexameric three-dimensional arrangement of their monomers (Figure 19) and play roles in a wide range of cellular processes [9]. The proteolytic reaction contributes to intracellular protein turnover, a fundamental housekeeping process across all living organisms [132] (Figure 18). However, a wide range of additional functions beyond aminopeptidase activity have also been attributed to M17 family members. M17 aminopeptidases from plants possess chaperone activity [133], which might contribute to their function in the stress response pathway [134], while in bacteria they play roles in site-specific DNA recombination [135], and further, can moderate transcription of key virulence factors [136]. Therefore, the family of M17 aminopeptidases is multifunctional, capable of performing diverse organism-specific functions far beyond peptide hydrolysis (Figure 18).
Leucyl aminopeptidases are also distributed in Apicomplexan protist parasites such as Plasmodium falciparum, the main agent of malaria in humans. The most important clinical stage of the complex P. falciparum life cycle [137], which has attracted the highest attention for the development of antimalarials, takes place in the human erythrocyte, where significant hemoglobin degradation occurs under the concerted action of endo- and exopeptidases [138]. PfA-M17 is involved in the final steps of hemoglobin digestion [139] and is currently a promising chemotherapeutic target as its inhibitors can kill parasites in vitro and in vivo (Figure 1) [9,140,141].
Through the technique of crystallography and X-ray diffraction, the three-dimensional structure of several members of this family has been elucidated, such as leucyl aminopeptidase 3 from Bos taurus, leucyl aminopeptidase (plant-type) from Solanum lycopersicum, PepA aminopeptidasa from Escherichia coli and other bacteria, and PfA-M17 from Plasmodium falciparum among others, being PfA-M17, joint with the mammalian enzyme, the more representative in tridimensional structure available at PDB, supporting the relevance of the search for new inhibitors as potential new antimalarial chemotherapy agents (Table 8, Figure 19).
Natural inhibitors of leucine aminopeptidases are scarce and have mainly been described from microorganisms sharing unspecific inhibition of APN and other M1 family inhibitors, such as actinonin, amastatin, bestatin, and various bestatin derivaties (Figure 12 and Figure 20) [18,139,142]. Several compounds from marine organisms have been described with anticancer and antiplasmodial activities [103,106,143,144,145,146]; however, only two of them have been linked with LAP inhibition or interaction [102,104,105]. In the next section, we review the information available regarding marine organisms as a promissory and still unexplored source of inhibitors of M17 enzyme inhibitors with biomedical relevance, mainly in cancer and malaria.

2.6. Inhibitors of M17 Leucyl Aminopeptidases from Marine Organisms

In the work of Pascual et al. [98], the screening of inhibitory activities in aqueous extracts from species belonging to the phyla Mollusca, Poriphera, Echinodermata, and Cnidaria from the Cuban coastline involved human LAP (hLAP) and a recombinant form of PfA-M17 (rPfA-M17), both leucil aminopeptidases. As a result of preliminary assays, inhibitory activity vs. hLAP was detected in the species Cenchritis muricatus, Lissodendoryx (Lissodendoryx) isodyctialis, Isostichopus badionotus, and Stichodactyla helianthus. Inhibitory activity against rPfA-M17 was detected in the species Cenchritis muricatus, Echinaster (Othilia) echinophorus, Isostichopus badionotus, Physalia physalis, Stichodactyla helianthus, and Bunodosoma granuliferum (specific inhibitory activity values are summarized in Table 9, Figure 16), i.e., in four different phyla. The clarification of all aqueous crude extracts with a 2.5% TCA treatment increased the recovery of specific inhibitory activities as compared to their detection in positive crude extracts. The treatment also allowed the identification of inhibitory activities from species that were negative after screening using aqueous crude extracts. This result indicated that this clarification step was useful in the elimination of contaminants and/or induced dissociation from endogenous inhibitor–target complexes that did not allow the detection of inhibitory components in crude extracts.
All the clarified extracts showed inhibitory activity against both peptidases: malarial rPfA-M17 and native human LAP (Table 10, Figure 16). These activities have a concave dose-response behavior, corroborating the presence of reversible inhibitory molecules with IC50 values in µg/mL for both enzymes tested (Table 10). Inhibition of rPfA-M17 with IC50 values up to ~100 µg/mL is detected for 6 of the 10 extracts (those of Cenchritis muricatus, Nerita perolonta, Lissodendoryx (Lissodendoryx) isodictyalis, Tripneustes ventricosus, Isostichopus badionotus, and Stichodactyla helianthus). Comparing the inhibitions on rPfA-M17 and hLAP, in all cases, the plasmodial enzyme was more susceptible than its human counterpart, with ratios of selectivity between 1.87 and 60 times. The most selective extract was from Nerita versicolor, an attractive result even if its IC50 value for the malarial enzyme is moderate. All of the treated extracts displayed a dose-dependent effect on a chloroquine-resistant Plasmodium falciparum strain (FcB1) cell’s viability, with the exception of Cenchritis muricatus, Stichodactyla helianthus, and Bunodosoma granuliferum. The best effects were obtained for Tripneustes ventricosus and Lissodendoryx (Lissodendoryx) isodictyalis. Particularly attractive were the T. ventricosus extracts that displayed a 300 times more potent effect on the FcB1 strain of P. falciparum than the human cancer cells, indicating parasite effect specificity. Additionally, this effect of the T. ventricosus extract on the FcB1 strain was stronger than the effect of bestatin (a pure compound). Due to the fact that IC50 for L. isodyctialis and T. ventricosus were lower on the FcB1 strain of P. falciparum than on the PfA-M17 recombinant enzyme, it is very likely that these extracts may contain not only PfA-M17 inhibitors but also other compounds active on other malarial targets. For example, for L. isodyctialis, inhibition of subtilisin from Bacillus licheniformes with an IC50 value of 3 µg/mL was described by Gonzalez et al. [39]. Another interesting result is the selectivity for rPfA-M17 regarding hLAP of Nerita versicolor extract showing effects on parasite growth with IC50 in the same order of enzyme inhibition, indicating that this species is also attractive. These results are the first and still only report of inhibition of M17 enzymes (human and plasmodial) by marine invertebrate species aqueous extracts and supports that sponges as well as marine invertebrates from other phyla such as mollusks, echinoderms, and cnidarians are a good and still underexplored source of potential anticancer and antimalarials associated with the inhibition of neutral aminopeptidases from the M1 and M17 families involved in these human pathologies.
M17 enzymes are not only a very well established target for malaria and other parasitic diseases but also for bacterial infections and chronic pathologies such as cancer. Bacterial LAPs (from gram-negative or -positive bacteria such as Escherichia coli, Aeromonas proteolytica, Streptomyces lividans, and Pseudomonas aeruginosa, among others) are important virulence factors [147]. Leucine aminopeptidase 3 in humans (LAP3) is associated with various diseases and cancers, such as breast cancer and ovarian cancer [148]. Recently, Yang et al. [149] identified two compounds named compounds 5 and 6 (Figure 21) from 43 natural marine products screened as new inhibitors of LAP3 (from K562 cells with overexpression of LAP3). The inhibition of LAP3 at 30 µM by these two compounds was stronger than that of bestatin used as a control of inhibition in the same conditions. The authors explored the anticancer properties of these new compounds in different models of breast cancer. The results showed that compounds 5 and 6 displayed stronger antiproliferative activity of the breast cancer tumor cells MDA-MB-231 at 30 µM than bestatin. Additionally, both compounds 5 and 6 displayed a more potent suppression effect on the migration of MDA-MB-231 cells than bestatin (the effect of compound 5 was stronger than that of compound 6). It is well established that LAP3 plays an important role in the metastasis of breast cancer; hence LAP3 inhibitors may have a remarkable effect on the treatment of breast cancer [149].

3. Conclusions

Marine biodiversity is an important and promising source of inhibitors of metalloexopeptidases from different families, in particular M1 and M17 enzymes with biomedical applications in human diseases. The results reviewed in the present contribution support and encourage further fundamental applicative studies with inhibitors isolated from marine species in different biomedical models associated with the activity of these families of exopeptidases.

Author Contributions

Conceptualization, I.P.A. and F.X.A.; writing—original draft preparation I.P.A., F.A.G., M.E.V.T., Y.A.S., D.O.d.S., B.S.R., I.F., M.S. and F.X.A.; writing—review and editing, I.P.A., F.A.G. and F.X.A.; visualization, I.P.A. and M.E.V.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the French ANR-12-BS07-0020 project MAMMAMIA: “design of potential anti MAlarial M1/M17 AMinopeptiIdase Agents” and UH-CIM project: “New inhibitors of aminopeptidases with potential applications in cancer” (2020–2023).

Data Availability Statement

Not applicable.

Acknowledgments

This contribution is dedicated to María de los Angeles Chávez, renowned Cuban Biochemistry Professor, founder of the teaching of Biochemistry in Cuba and the Center for Protein Studies at the University of Havana. She significantly contributed to the knowledge in the field of peptidase inhibitors of different mechanistic classes isolated from Cuban marine biodiversity. To Jean Louis Charli, IBT-UNAM, Cuernavaca, Mexico, for the revision of the manuscript and useful comments. To Aymara Cabrera Munoz, from the Center for Protein Studies, Faculty of Biology, University of Havana, who kindly supplied images for Figure 4. To José Espinosa, PhD from ICIMAR, CITMA, Cuba, who kindly supplied the pictures of the marine species. To IFS-OPCW research grants 3276/1, 3276/2, 3276/3, to Isel Pascual Alonso. To IUBMB mid-career fellowship program for supporting the research stay of Isel Pascual Alonso at Laboratory MCAM, UMR 7245, MNHN, Paris, in 2014 and in Instituto de Biotecnología, UNAM, Cuernavaca, Mexico, in 2017. To the French ANR-12-BS07-0020 project MAMMAMIA: “design of potential anti MAlarial M1/M17 AMinopeptiIdase Agents”. To UH-CIM project: “New inhibitors of aminopeptidases with potential applications in cancer” (2020–2023).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rawlings, N.D.; Barrett, A.J.; Thomas, P.D.; Huang, X.; Bateman, A.; Finn, R.D. The Merops Database of Proteolytic Enzymes, Their Substrates and Inhibitors in 2017 and a Comparison with Peptidases in the Panther Database. Nucleic Acids Res. 2018, 46, D624–D632. [Google Scholar] [CrossRef] [PubMed]
  2. Drag, M.; Salvesen, G.S. Emerging Principles in Protease-Based Drug Discovery. Nat. Rev. Drug Discov. 2010, 9, 690–701. [Google Scholar] [CrossRef] [PubMed]
  3. Deu, E.; Verdoes, M.; Bogyo, M. New Approaches for Dissecting Protease Functions to Improve Probe Development and Drug Discovery. Nat. Struct. Mol. Biol. 2012, 19, 9–16. [Google Scholar] [CrossRef] [PubMed]
  4. Kryvalap, Y.; Czyzyk, J. The Role of Proteases and Serpin Protease Inhibitors in Β-Cell Biology and Diabetes. Biomolecules 2022, 12, 67. [Google Scholar] [CrossRef]
  5. Rai, M.; Curley, M.; Coleman, Z.; Demontis, F. Contribution of Proteases to the Hallmarks of Aging and to Age-Related Neurodegeneration. Aging Cell 2022, 21, e13603. [Google Scholar] [CrossRef]
  6. Verhulst, E.; Garnier, D.; De Meester, I.; Bauvois, B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers 2022, 14, 624. [Google Scholar] [CrossRef]
  7. Newman, D.J.; Cragg, G.M. Drugs and Drug Candidates from Marine Sources: An Assessment of the Current State of Play. Planta Med. 2016, 82, 775–789. [Google Scholar] [CrossRef]
  8. Drinkwater, N.; Lee, J.; Yang, W.; Malcolm, T.R.; McGowan, S. M1 Aminopeptidases as Drug Targets: Broad Applications or Therapeutic Niche? FEBS J. 2017, 284, 1473–1488. [Google Scholar] [CrossRef]
  9. Drinkwater, N.; Malcolm, T.R.; McGowan, S. M17 Aminopeptidases Diversify Function by Moderating Their Macromolecular Assemblies and Active Site Environment. Biochimie 2019, 166, 38–51. [Google Scholar] [CrossRef]
  10. Hammers, D.; Carothers, K.; Lee, S. The Role of Bacterial Proteases in Microbe and Host-Microbe Interactions. Curr. Drug Targets 2022, 23, 222–239. [Google Scholar] [CrossRef]
  11. Carvalho, L.A.; Bernardes, G.J. The Impact of Activity-Based Protein Profiling in Malaria Drug Discovery. ChemMedChem 2022, 17, e202200174. [Google Scholar] [CrossRef] [PubMed]
  12. Beltran-Hortelano, I.; Alcolea, V.; Font, M.; Pérez-Silanes, S. Examination of Multiple Trypanosoma cruzi Targets in a New Drug Discovery Approach for Chagas Disease. Bioorganic Med. Chem. 2022, 58, 116577. [Google Scholar] [CrossRef] [PubMed]
  13. Vermelho, A.B.; Cardoso, V.; Mansoldo, F.R.P.; Supuran, C.T.; Cedrola, S.M.L.; Rodrigues, I.A.; Rodrigues, G.C. Chagas Disease: Drug Development and Parasite Targets. In Antiprotozoal Drug Development and Delivery; Springer: Berlin/Heidelberg, Germany, 2022; pp. 49–81. [Google Scholar]
  14. Mukherjee, R.; Dikic, I. Regulation of Host-Pathogen Interactions Via the Ubiquitin System. Annu. Rev. Microbiol. 2022, 76, 211–233. [Google Scholar] [CrossRef] [PubMed]
  15. Salomon, E.; Schmitt, M.; Marapaka, A.K.; Stamogiannos, A.; Revelant, G.; Schmitt, C.; Alavi, S.; Florent, I.; Addlagatta, A.; Stratikos, E.; et al. Aminobenzosuberone Scaffold as a Modular Chemical Tool for the Inhibition of Therapeutically Relevant M1 Aminopeptidases. Molecules 2018, 23, 2607. [Google Scholar] [CrossRef] [PubMed]
  16. Albiston, A.L.; Ye, S.; Chai, S.Y. Membrane Bound Members of the M1 Family: More Than Aminopeptidases. Protein Pept. Lett. 2004, 11, 491–500. [Google Scholar] [CrossRef] [PubMed]
  17. Carl-McGrath, S.; Lendeckel, U.; Ebert, M.; Röcken, C. Ectopeptidases in Tumour Biology: A Review. Histol. Histopathol. 2006, 12, 1339–1353. [Google Scholar]
  18. Mucha, A.; Drag, M.; Dalton, J.P.; Kafarski, P. Metallo-Aminopeptidase Inhibitors. Biochimie 2010, 92, 1509–1529. [Google Scholar] [CrossRef] [PubMed]
  19. Amin, S.A.; Adhikari, N.; Jha, T. Design of Aminopeptidase N Inhibitors as Anti-Cancer Agents. J. Med. Chem. 2018, 61, 6468–6490. [Google Scholar] [CrossRef]
  20. Alvarez, C.; Pazos, F.; Soto, C.; Laborde, R.; Lanio, M.E. Pore-Forming Toxins from Sea Anemones: From Protein-Membrane Interaction to Its Implications for Developing Biomedical Applications. In Advances in Biomembranes and Lipid Self-Assembly; Elsevier: Amsterdam, The Netherlands, 2020; pp. 129–183. [Google Scholar]
  21. Alvarez, C.; Soto, C.; Cabezas, S.; Alvarado-Mesén, J.; Laborde, R.; Pazos, F.; Ros, U.; Hernández, A.M.; Lanio, M.E. Panorama of the Intracellular Molecular Concert Orchestrated by Actinoporins, Pore-Forming Toxins from Sea Anemones. Toxins 2021, 13, 567. [Google Scholar] [CrossRef]
  22. Martell, E.M.; González-Garcia, M.; Ständker, L.; Otero-González, A.J. Host Defense Peptides as Immunomodulators: The Other Side of the Coin. Peptides 2021, 146, 170644. [Google Scholar] [CrossRef]
  23. Rodríguez, A.A.; Otero-González, A.; Ghattas, M.; Ständker, L. Discovery, Optimization, and Clinical Application of Natural Antimicrobial Peptides. Biomedicines 2021, 9, 1381. [Google Scholar] [CrossRef] [PubMed]
  24. Riccio, G.; Ruocco, N.; Mutalipassi, M.; Costantini, M.; Zupo, V.; Coppola, D.; De Pascale, D.; Lauritano, C. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms. Biomolecules 2020, 10, 1007. [Google Scholar] [CrossRef] [PubMed]
  25. Nakao, Y.; Fusetani, N. Enzyme Inhibitors from Marine Invertebrates. J. Nat. Prod. 2007, 70, 689–710. [Google Scholar] [CrossRef]
  26. Pujiastuti, D.Y.; Amin, M.N.G.; Alamsjah, M.A.; Hsu, J.-L. Marine Organisms as Potential Sources of Bioactive Peptides That Inhibit the Activity of Angiotensin I-Converting Enzyme: A Review. Molecules 2019, 24, 2541. [Google Scholar] [CrossRef]
  27. Tischler, D. A Perspective on Enzyme Inhibitors from Marine Organisms. Mar. Drugs 2020, 18, 431. [Google Scholar] [CrossRef] [PubMed]
  28. Moodie, L.W.K.; Sepčić, K.; Turk, T.; Frangež, R.; Svenson, J. Natural Cholinesterase Inhibitors from Marine Organisms. Nat. Prod. Rep. 2019, 36, 1053–1092. [Google Scholar] [CrossRef]
  29. Alonso-del-Rivero, M.; Trejo, S.A.; Rodriguez de la Vega, M.; González, Y.; Bronsoms, S.; Canals, F.; Delfín, J.; Diaz, J.; Aviles, F.X.; Chávez, M.A. A Novel Metallocarboxypeptidase-Like Enzyme from the Marine Annelid Sabellastarte magnifica–a Step into the Invertebrate World of Proteases. FEBS J. 2009, 276, 4875–4890. [Google Scholar] [CrossRef]
  30. Alonso, I.P.; Méndez, L.R.; Almeida, F.; Tresano, M.E.V.; Sánchez, Y.A.; Hernández-Zanuy, A.; Álvarez-Lajonchere, L.; Díaz, D.; Sánchez, B.; Florent, I. Marine Organisms: A Source of Biomedically Relevant Metallo M1, M2 and M17 Exopeptidase Inhibitors. Rev. Cuba. Cienc. Biológicas 2020, 8, 1–36. [Google Scholar]
  31. Chávez, M.; Delfín, J.; Díaz, J.; Pérez, U.; Martínez, J.; González, J.; Márquez, M.; Más, R. Caracterización de un Inhibidor de Proteasas Obtenido de la Anémona S. helianthus. Rev. CENIC 1988, 19, 82. [Google Scholar]
  32. Delfin, J.; Gonzalez, Y.; Diaz, J.; Chavez, M. Proteinase Inhibitor from Stichodactyla helianthus: Purification, Characterization and Immobilization. Arch. Med. Res. 1994, 25, 199–204. [Google Scholar]
  33. Delfin, J.; Martinez, I.; Antuch, W.; Morera, V.; Gonzalez, Y.; Rodriguez, R.; Marquez, M.; Saroyan, A.; Larionova, N.; Diaz, J. Purification, Characterization and Immobilization of Proteinase Inhibitors from Stichodactyla helianthus. Toxicon 1996, 34, 1367–1376. [Google Scholar] [CrossRef] [PubMed]
  34. Lenarčič, B.; Ritonja, A.; Štrukelj, B.; Turk, B.; Turk, V. Equistatin, a New Inhibitor of Cysteine Proteinases from Actinia equina, Is Structurally Related to Thyroglobulin Type-1 Domain. J. Biol. Chem. 1997, 272, 13899–13903. [Google Scholar] [CrossRef] [PubMed]
  35. González, Y.; Araujo, M.; Oliva, M.; Sampaio, C.; Chávez, M. Purification and Preliminary Characterization of a Plasma Kallikrein Inhibitor Isolated from Sea Hares Aplysia dactylomela Rang, 1828. Toxicon 2004, 43, 219–223. [Google Scholar] [CrossRef] [PubMed]
  36. Reytor, M.L.; González, Y.; Pascual, I.; Hernández, A.; Chávez M, Á.; Alonso del Rivero, M. Screening of Protease Inhibitory Activity in Extracts of Five Ascidian Species from Cuban Coasts. Biotecnol. Apl. 2011, 28, 77–82. [Google Scholar]
  37. Alonso-Del-Rivero, M.; Trejo, S.; Reytor, M.L.; Rodriguez-De-La-Vega, M.; Delfin, J.; Diaz, J.; Gonzalez, M.L.R.; Canals, F.; Chavez, M.A.; Aviles, F.X. Tri-Domain Bifunctional Inhibitor of Metallocarboxypeptidases a and Serine Proteases Isolated from Marine Annelid Sabellastarte magnifica. J. Biol. Chem. 2012, 287, 15427–15438. [Google Scholar] [CrossRef] [PubMed]
  38. Salas-Sarduy, E.; Cabrera-Muñoz, A.; Cauerhff, A.; González-González, Y.; Trejo, S.A.; Chidichimo, A.; de los Angeles Chávez-Planes, M.; José Cazzulo, J. Antiparasitic Effect of a Fraction Enriched in Tight-Binding Protease Inhibitors Isolated from the Caribbean Coral Plexaura homomalla. Exp. Parasitol. 2013, 135, 611–622. [Google Scholar] [CrossRef]
  39. González, L.; Sánchez, R.E.; Rojas, L.; Pascual, I.; García-Fernández, R.; Chávez, M.A.; Betzel, C. Screening of Protease Inhibitory Activity in Aqueous Extracts of Marine Invertebrates from Cuban Coast. Am. J. Anal. Chem. 2016, 7, 319–331. [Google Scholar] [CrossRef]
  40. Salas-Sarduy, E.; Guerra, Y.; Covaleda Cortés, G.; Avilés, F.X.; Chávez Planes, M.A. Identification of Tight-Binding Plasmepsin Ii and Falcipain 2 Inhibitors in Aqueous Extracts of Marine Invertebrates by the Combination of Enzymatic and Interaction-Based Assays. Mar. Drugs 2017, 15, 123. [Google Scholar] [CrossRef]
  41. Covaleda, G.; Trejo, S.A.; Salas-Sarduy, E.; del Rivero, M.A.; Chavez, M.A.; Aviles, F.X. Intensity Fading Maldi-Tof Mass Spectrometry and Functional Proteomics Assignments to Identify Protease Inhibitors in Marine Invertebrates. J. Proteom. 2017, 165, 75–92. [Google Scholar] [CrossRef]
  42. Hong, T.T.; Dat, T.T.H.; Cuong, P.V.; Cuc, N.T.K. Protease Inhibitors from Marine Sponge and Sponge-Associated Microorganisms. Vietnam. J. Sci. Technol. 2018, 56, 405–423. [Google Scholar] [CrossRef]
  43. Ikegami, S.; Kobayashi, H.; Myotoishi, Y.; Ohta, S.; Kato, K.H. Selective Inhibition of Exoplasmic Membrane Fusion in Echinoderm Gametes with Jaspisin, a Novel Antihatching Substance Isolated from a Marine Sponge. J. Biol. Chem. 1994, 269, 23262–23267. [Google Scholar] [CrossRef] [PubMed]
  44. Kato, K.H.; Takemoto, K.; Kato, E.; Miyazaki, K.; Kobayashi, H.; Ikegami, S. Inhibition of Sea Urchin Fertilization by Jaspisin, a Specific Inhibitor of Matrix Metalloendoproteinase. Dev. Growth Differ. 1998, 40, 221–230. [Google Scholar] [CrossRef] [PubMed]
  45. Fusetani, N.; Fujita, M.; Nakao, Y.; Matsunaga, S.; van Soest, R.W. Tokaramide a, a New Cathepsin B Inhibitor from the Marine Sponge Theonella Aff. mirabilis. Bioorganic Med. Chem. Lett. 1999, 9, 3397–3402. [Google Scholar] [CrossRef] [PubMed]
  46. Fujita, M.; Nakao, Y.; Matsunaga, S.; van Soest, R.W.; Itoh, Y.; Seiki, M.; Fusetani, N. Callysponginol Sulfate a, an Mt1-Mmp Inhibitor Isolated from the Marine Sponge Callyspongia tuncata. J. Nat. Prod. 2003, 66, 569–571. [Google Scholar] [CrossRef] [PubMed]
  47. Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Yamashita, J.; Van Soest, R.W.; Fusetani, N. Ageladine A: An Antiangiogenic Matrixmetalloproteinase Inhibitor from the Marine Sponge Agelas N Akamurai. J. Am. Chem. Soc. 2003, 125, 15700–15701. [Google Scholar] [CrossRef]
  48. Shim, J.S.; Lee, H.-S.; Shin, J.; Kwon, H.J. Psammaplin a, a Marine Natural Product, Inhibits Aminopeptidase N and Suppresses Angiogenesis in Vitro. Cancer Lett. 2004, 203, 163–169. [Google Scholar] [CrossRef]
  49. Pascual, I.; Gil-Parrado, S.; Cisneros, M.; Joseph-Bravo, P.; Dıaz, J.; Possani, L.D.; Charli, J.L.; Chávez, M. Purification of a Specific Inhibitor of Pyroglutamyl Aminopeptidase Ii from the Marine Annelide Hermodice carunculata: In Vivo Effects in Rodent Brain. Int. J. Biochem. Cell Biol. 2004, 36, 138–152. [Google Scholar] [CrossRef]
  50. Thomas, N.V.; Kim, S.-K. Metalloproteinase Inhibitors: Status and Scope from Marine Organisms. Biochem. Res. Int. 2010, 2010, 845975. [Google Scholar] [CrossRef]
  51. del Rivero, M.A.; Reytor, M.L.; Trejo, S.A.; Chávez, M.A.; Avilés, F.X.; Reverter, D. A Noncanonical Mechanism of Carboxypeptidase Inhibition Revealed by the Crystal Structure of the Tri-Kunitz Smci in Complex with Human Cpa4. Structure 2013, 21, 1118–1126. [Google Scholar]
  52. Covaleda, G.; del Rivero, M.A.; Chávez, M.A.; Avilés, F.X.; Reverter, D. Crystal Structure of Novel Metallocarboxypeptidase Inhibitor from Marine Mollusk Nerita versicolor in Complex with Human Carboxypeptidase A4. J. Biol. Chem. 2012, 287, 9250–9258. [Google Scholar] [CrossRef]
  53. Cabrera-Muñoz, A.; Valiente, P.A.; Rojas, L.; Antigua, M.A.D.R.; Pires, J.R. Nmr Structure of Cmpi-Ii, a Non-Classical Kazal Protease Inhibitor: Understanding Its Conformational Dynamics and Subtilisin a Inhibition. J. Struct. Biol. 2019, 206, 280–294. [Google Scholar] [CrossRef] [PubMed]
  54. Pascual Alonso, I.; Rivera Méndez, L.; Valdés-Tresanco, M.E.; Bounaadja, L.; Schmitt, M.; Arrebola Sánchez, Y.; Alvarez Lajonchere, L.; Charli, J.L.; Florent, I. Biochemical Evidences for M1-, M17- and M18-Like Aminopeptidases in Marine Invertebrates from Cuban Coastline. Z. Für Nat. C 2020, 75, 397–407. [Google Scholar] [CrossRef] [PubMed]
  55. Sarfaraj, H.M.; Sheeba, F.; Saba, A.; Khan, M. Marine Natural Products: A Lead for Anti-Cancer; NISCAIR-CSIR: New Delhi, India, 2012. [Google Scholar]
  56. Nakao, Y.; Oku, N.; Matsunaga, S.; Fusetani, N. Cyclotheonamides E2 and E3, New Potent Serine Protease Inhibitors from the Marine Sponge of the Genus Theonella. J. Nat. Prod. 1998, 61, 667–670. [Google Scholar] [CrossRef] [PubMed]
  57. Hanessian, S.; Tremblay, M.; Petersen, J.F. The N-Acyloxyiminium Ion Aza-Prins Route to Octahydroindoles: Total Synthesis and Structural Confirmation of the Antithrombotic Marine Natural Product Oscillarin. J. Am. Chem. Soc. 2004, 126, 6064–6071. [Google Scholar] [CrossRef]
  58. Gunasekera, S.P.; McCarthy, P.J.; Longley, R.E.; Pomponi, S.A.; Wright, A.E.; Lobkovsky, E.; Clardy, J. Discorhabdin P, a New Enzyme Inhibitor from a Deep-Water Caribbean Sponge of the Genus Batzella. J. Nat. Prod. 1999, 62, 173–175. [Google Scholar] [CrossRef]
  59. Gunasekera, S.P.; McCarthy, P.J.; Longley, R.E.; Pomponi, S.A.; Wright, A.E. Secobatzellines a and B, Two New Enzyme Inhibitors from a Deep-Water Caribbean Sponge of the Genus Batzella. J. Nat. Prod. 1999, 62, 1208–1211. [Google Scholar] [CrossRef] [PubMed]
  60. Hu, J.F.; Schetz, J.A.; Kelly, M.; Peng, J.N.; Ang, K.K.; Flotow, H.; Leong, C.Y.; Ng, S.B.; Buss, A.D.; Wilkins, S.P. New Antiinfective and Human 5-Ht2 Receptor Binding Natural and Semisynthetic Compounds from the Jamaican Sponge Smenospongia aurea. J. Nat. Prod. 2002, 65, 476–480. [Google Scholar] [CrossRef] [PubMed]
  61. Fujita, M.; Nakao, Y.; Matsunaga, S.; Nishikawa, T.; Fusetani, N. Sodium 1-(12-Hydroxy) Octadecanyl Sulfate, an Mmp2 Inhibitor, Isolated from a Tunicate of the Family Polyclinidae. J. Nat. Prod. 2002, 65, 1936–1938. [Google Scholar] [CrossRef]
  62. Joe, M.-J.; Kim, S.-N.; Choi, H.-Y.; Shin, W.-S.; Park, G.-M.; Kang, D.-W.; Kim, Y.K. The Inhibitory Effects of Eckol and Dieckol from Ecklonia stolonifera on the Expression of Matrix Metalloproteinase-1 in Human Dermal Fibroblasts. Biol. Pharm. Bull. 2006, 29, 1735–1739. [Google Scholar] [CrossRef]
  63. Harper, J.W.; Powers, J.C. Inhibitors of Metallo-Proteases. In Proteinase Inhibitors; Elsevier: Amsterdam, The Netherlands, 1986; pp. 219–298. [Google Scholar]
  64. Rawlings, N.D.; Barrett, A.J. Evolutionary Families of Peptidases. Biochem. J. 1993, 290, 205–218. [Google Scholar] [CrossRef]
  65. Rawlings, N.D.; Barrett, A.J. [13] Evolutionary Families of Metallopeptidases. In Methods in Enzymology; Elsevier: Amsterdam, The Netherlands, 1995; pp. 183–228. [Google Scholar]
  66. Reeck, G.R.; de Haën, C.; Teller, D.C.; Doolittle, R.F.; Fitch, W.M.; Dickerson, R.E.; Chambon, P.; McLachlan, A.D.; Margoliash, E.; Jukes, T.H.; et al. Homology in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of It. Cell 1987, 50, 667. [Google Scholar] [CrossRef] [PubMed]
  67. Haeggström, J.Z.; Nordlund, P.; Thunnissen, M.M. Functional Properties and Molecular Architecture of Leukotriene A4 Hydrolase, a Pivotal Catalyst of Chemotactic Leukotriene Formation. Sci. World J. 2002, 2, 1734–1749. [Google Scholar] [CrossRef] [PubMed]
  68. Fukasawa, K.M.; Fukasawa, K.; Harada, M.; Hirose, J.; Izumi, T.; Shimizu, T. Aminopeptidase B Is Structurally Related to Leukotriene-A4 Hydrolase but Is Not a Bifunctional Enzyme with Epoxide Hydrolase Activity. Biochem. J. 1999, 339, 497–502. [Google Scholar] [CrossRef] [PubMed]
  69. Klinke, T.; Rump, A.; Pönisch, R.; Schellenberger, W.; Müller, E.C.; Otto, A.; Klimm, W.; Kriegel, T.M. Identification and Characterization of Caape2–a Neutral Arginine/Alanine/Leucine-Specific Metallo-Aminopeptidase from Candida albicans. FEMS Yeast Res. 2008, 8, 858–869. [Google Scholar] [CrossRef]
  70. Wong, A.H.M.; Zhou, D.; Rini, J.M. The X-Ray Crystal Structure of Human Aminopeptidase N Reveals a Novel Dimer and the Basis for Peptide Processing. J. Biol. Chem. 2012, 287, 36804–36813. [Google Scholar] [CrossRef]
  71. Thunnissen, M.M.; Nordlund, P.; Haeggström, J.Z. Crystal Structure of Human Leukotriene A4 Hydrolase, a Bifunctional Enzyme in Inflammation. Nat. Struct. Biol. 2001, 8, 131–135. [Google Scholar] [CrossRef]
  72. Kyrieleis, O.J.; Goettig, P.; Kiefersauer, R.; Huber, R.; Brandstetter, H. Crystal Structures of the Tricorn Interacting Factor F3 from Thermoplasma Acidophilum, a Zinc Aminopeptidase in Three Different Conformations. J. Mol. Biol. 2005, 349, 787–800. [Google Scholar] [CrossRef]
  73. Ito, K.; Nakajima, Y.; Onohara, Y.; Takeo, M.; Nakashima, K.; Matsubara, F.; Ito, T.; Yoshimoto, T. Crystal Structure of Aminopeptidase N (Proteobacteria Alanyl Aminopeptidase) from Escherichia coli and Conformational Change of Methionine 260 Involved in Substrate Recognition. J. Biol. Chem. 2006, 281, 33664–33676. [Google Scholar] [CrossRef]
  74. McGowan, S.; Porter, C.J.; Lowther, J.; Stack, C.M.; Golding, S.J.; Skinner-Adams, T.S.; Trenholme, K.R.; Teuscher, F.; Donnelly, S.M.; Grembecka, J.; et al. Structural Basis for the Inhibition of the Essential Plasmodium Falciparum M1 Neutral Aminopeptidase. Proc. Natl. Acad. Sci. USA 2009, 106, 2537–2542. [Google Scholar] [CrossRef]
  75. Harbut, M.B.; Velmourougane, G.; Dalal, S.; Reiss, G.; Whisstock, J.C.; Onder, O.; Brisson, D.; McGowan, S.; Klemba, M.; Greenbaum, D.C. Bestatin-Based Chemical Biology Strategy Reveals Distinct Roles for Malaria M1-and M17-Family Aminopeptidases. Proc. Natl. Acad. Sci. USA 2011, 108, E526–E534. [Google Scholar] [CrossRef]
  76. Salomon, E.; Schmitt, M.; Mouray, E.; McEwen, A.G.; Bounaadja, L.; Torchy, M.; Poussin-Courmontagne, P.; Alavi, S.; Tarnus, C.; Cavarelli, J.; et al. Aminobenzosuberone Derivatives as Pfa-M1 Inhibitors: Molecular Recognition and Antiplasmodial Evaluation. Bioorganic Chem. 2020, 98, 103750. [Google Scholar] [CrossRef] [PubMed]
  77. Yang, Y.; Liu, C.; Lin, Y.-L.; Li, F. Structural Insights into Central Hypertension Regulation by Human Aminopeptidase A. J. Biol. Chem. 2013, 288, 25638–25645. [Google Scholar] [CrossRef] [PubMed]
  78. Kochan, G.; Krojer, T.; Harvey, D.; Fischer, R.; Chen, L.; Vollmar, M.; von Delft, F.; Kavanagh, K.L.; Brown, M.A.; Bowness, P.; et al. Crystal Structures of the Endoplasmic Reticulum Aminopeptidase-1 (Erap1) Reveal the Molecular Basis for N-Terminal Peptide Trimming. Proc. Natl. Acad. Sci. USA 2011, 108, 7745–7750. [Google Scholar] [CrossRef] [PubMed]
  79. Chen, J.; Wang, Y.; Zhong, Q.; Wu, Y.; Xia, W. Purification and Characterization of a Novel Angiotensin-I Converting Enzyme (Ace) Inhibitory Peptide Derived from Enzymatic Hydrolysate of Grass Carp Protein. Peptides 2012, 33, 52–58. [Google Scholar] [CrossRef] [PubMed]
  80. Gago, F. Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs. Mar. Drugs 2023, 21, 100. [Google Scholar] [CrossRef] [PubMed]
  81. Omar, A.M.; Mohammad, K.A.; Sindi, I.A.; Mohamed, G.A.; Ibrahim, S.R.M. Unveiling the Efficacy of Sesquiterpenes from Marine Sponge Dactylospongia elegans in Inhibiting Dihydrofolate Reductase Using Docking and Molecular Dynamic Studies. Molecules 2023, 28, 1292. [Google Scholar] [CrossRef] [PubMed]
  82. Joseph-Bravo, P.; Jaimes-Hoy, L.; Uribe, R.M.; Charli, J.L. 60 Years of Neuroendocrinology: TRH, the First Hypophysiotropic Releasing Hormone Isolated: Control of the Pituitary–Thyroid Axis. J. Endocrinol. 2015, 226, T85–T100. [Google Scholar] [CrossRef]
  83. Kronenberg, H.M.; Shlomo Melmed, M.D.; Polonsky, K.S.; Wilson, J.D.; Foster, D.W.; Kronenberg, H.M. Williams Textbook of Endocrinology; Saunders: Philadelphia, PA, USA, 2002. [Google Scholar]
  84. Charli, J.L.; Rodríguez-Rodríguez, A.; Hernández-Ortega, K.; Cote-Vélez, A.; Uribe, R.M.; Jaimes-Hoy, L.; Joseph-Bravo, P. The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target? Front. Pharm. 2020, 11, 640. [Google Scholar] [CrossRef]
  85. A Kelly, J. Thyrotropin-Releasing Hormone: Basis and Potential for Its Therapeutic Use. Essays Biochem. 1995, 30, 133. [Google Scholar]
  86. Charli, J.-L.; Mendez, M.; Vargas, M.-A.; Cisneros, M.; Assai, M.; Joseph-Bravo, P.; Wilk, S. Pyroglutamyl Peptidase Ii Inhibition Specifically Increases Recovery of Trh Released from Rat Brain Slices. Neuropeptides 1989, 14, 191–196. [Google Scholar] [CrossRef]
  87. Kelly, J.A.; Slator, G.R.; Tipton, K.F.; Williams, C.H.; Bauer, K. Kinetic Investigation of the Specificity of Porcine Brain Thyrotropin-Releasing Hormone-Degrading Ectoenzyme for Thyrotropin-Releasing Hormone-Like Peptides. J. Biol. Chem. 2000, 275, 16746–16751. [Google Scholar] [CrossRef] [PubMed]
  88. Kelly, J.A.; Scalabrino, G.A.; Slator, G.R.; Cullen, A.A.; Gilmer, J.F.; Lloyd, D.G.; Bennett, G.W.; Bauer, K.; Tipton, K.F.; Williams, C.H. Structure–Activity Studies with High-Affinity Inhibitors of Pyroglutamyl-Peptidase Ii. Biochem. J. 2005, 389, 569–576. [Google Scholar] [CrossRef] [PubMed]
  89. Cruz, R.; Vargas, M.A.; Uribe, R.M.; Pascual, I.; Lazcano, I.; Yiotakis, A.; Matziari, M.; Joseph-Bravo, P.; Charli, J.-L. Anterior Pituitary Pyroglutamyl Peptidase Ii Activity Controls Trh-Induced Prolactin Release. Peptides 2008, 29, 1953–1964. [Google Scholar] [CrossRef] [PubMed]
  90. Sinko, R.; Mohácsik, P.; Kővári, D.; Penksza, V.; Wittmann, G.; Mácsai, L.; Fonseca, T.L.; Bianco, A.C.; Fekete, C.; Gereben, B. Different Hypothalamic Mechanisms Control Decreased Circulating Thyroid Hormone Levels in Infection and Fasting-Induced Non-Thyroidal Illness Syndrome in Male Thyroid Hormone Action Indicator Mice. Thyroid 2023, 33, 109–118. [Google Scholar] [CrossRef]
  91. Barnieh, F.M.; Loadman, P.M.; Falconer, R.A. Is Tumour-Expressed Aminopeptidase N (Apn/Cd13) Structurally and Functionally Unique? Biochim. Biophys. Acta (BBA)-Rev. Cancer 2021, 1876, 188641. [Google Scholar] [CrossRef]
  92. Wickström, M.; Larsson, R.; Nygren, P.; Gullbo, J. Aminopeptidase N (Cd13) as a Target for Cancer Chemotherapy. Cancer Sci. 2011, 102, 501–508. [Google Scholar] [CrossRef]
  93. Ni, J.; Wang, X.; Shang, Y.; Li, Y.; Chen, S. Cd13 Inhibition Augments Dr4-Induced Tumor Cell Death in a P-Erk1/2-Independent Manner. Cancer Biol. Med. 2021, 18, 569. [Google Scholar] [CrossRef]
  94. Schreiter, A.; Gore, C.; Labuz, D.; Fournie-Zaluski, M.C.; Roques, B.P.; Stein, C.; Machelska, H. Pain Inhibition by Blocking Leukocytic and Neuronal Opioid Peptidases in Peripheral Inflamed Tissue. FASEB J. 2012, 26, 5161–5171. [Google Scholar] [CrossRef]
  95. Bonnard, E.; Poras, H.; Nadal, X.; Maldonado, R.; Fournié-Zaluski, M.C.; Roques, B.P. Long-Lasting Oral Analgesic Effects of N-Protected Aminophosphinic Dual Enk Ephalinase Inhibitors (Denki S) in Peripherally Controlled Pain. Pharmacol. Res. Perspect. 2015, 3, e0116. [Google Scholar] [CrossRef]
  96. Arrebola, Y.; Rivera, L.; Pedroso, A.; McGuire, R.; Tresanco, M.E.V.; Bergado, G.; Charli, J.-L.; Sánchez, B.; Alonso, I.P. Bacitracin Is a Non-Competitive Inhibitor of Porcine M1 Family Neutral and Glutamyl Aminopeptidases. Nat. Prod. Res. 2021, 35, 2958–2962. [Google Scholar] [CrossRef]
  97. Melzig, M.F.; Bormann, H. Betulinic Acid Inhibits Aminopeptidase N Activity. Planta Med. 1998, 64, 655–657. [Google Scholar] [CrossRef] [PubMed]
  98. Pascual Alonso, I.; Bounaadja, L.; Sánchez, L.; Rivera, L.; Tarnus, C.; Schmitt, M.; Garcia, G.; Diaz, L.; Hernandez-Zanuy, A.; Sánchez, B.; et al. Aqueous Extracts of Marine Invertebrates from Cuba Coastline Display Neutral Aminopeptidase Inhibitory Activities and Effects on Cancer Cells and Plasmodium Falciparum Parasites. Indian J. Nat. Prod. Resour. 2017, 8, 107–119. [Google Scholar]
  99. Pascual, I.; Valiente, P.A.; García, G.; Valdés-Tresanco, M.E.; Arrebola, Y.; Díaz, L.; Bounaadja, L.; Uribe, R.M.; Pacheco, M.C.; Florent, I.; et al. Discovery of Novel Non-Competitive Inhibitors of Mammalian Neutral M1 Aminopeptidase (Apn). Biochimie 2017, 142, 216–225. [Google Scholar] [CrossRef]
  100. Pascual-Alonso, I.; Alonso-Bosch, R.; Cabrera-Muñoz, A.; Perera, W.H.; Charli, J.L. Methanolic Extracts of Paratoid Gland Secretions from Cuban Peltophryne Toads Contain Inhibitory Activities against Peptidases with Biomedical Relevance. Biotecnol. Apl. 2019, 36, 2221–2227. [Google Scholar]
  101. Alonso, I.P.; Méndez, L.R.; García, F.A.; Valdés-Tresanco, M.E.; Bosch, R.A.; Perera, W.H.; Sánchez, Y.A.; Bergado, G.; Ramírez, B.S.; Charli, J.-L. Bufadienolides Preferentially Inhibit Aminopeptidase N among Mammalian Metallo-Aminopeptidases; Relationship with Effects on Human Melanoma Mewo Cells. Int. J. Biol. Macromol. 2023, 229, 825–837. [Google Scholar] [CrossRef] [PubMed]
  102. Wang, E.; Sorolla, M.A.; Krishnan, P.D.G.; Sorolla, A. From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds. Biomolecules 2020, 10, 248. [Google Scholar] [CrossRef] [PubMed]
  103. Malla, R.R.; Farran, B.; Nagaraju, G.P. Understanding the Function of the Tumor Microenvironment, and Compounds from Marine Organisms for Breast Cancer Therapy. World J. Biol. Chem. 2021, 12, 15. [Google Scholar] [CrossRef]
  104. Aldrich, L.N.; Burdette, J.E.; de Blanco, E.C.; Coss, C.C.; Eustaquio, A.S.; Fuchs, J.R.; Kinghorn, A.D.; MacFarlane, A.; Mize, B.K.; Oberlies, N.H.; et al. Discovery of Anticancer Agents of Diverse Natural Origin. J. Nat. Prod. 2022, 85, 702–719. [Google Scholar] [CrossRef]
  105. Nuzzo, G.; Senese, G.; Gallo, C.; Albiani, F.; Romano, L.; D’ippolito, G.; Manzo, E.; Fontana, A. Antitumor Potential of Immunomodulatory Natural Products. Mar. Drugs 2022, 20, 386. [Google Scholar] [CrossRef]
  106. Saeed, A.F.; Su, J.; Ouyang, S. Marine-Derived Drugs: Recent Advances in Cancer Therapy and Immune Signaling. Biomed. Pharmacother. 2021, 134, 111091. [Google Scholar] [CrossRef]
  107. Jung, J.H.; Sim, C.J.; Lee, C.-O. Cytotoxic Compounds from a Two-Sponge Association. J. Nat. Prod. 1995, 58, 1722–1726. [Google Scholar] [CrossRef] [PubMed]
  108. Shin, J.; Lee, H.-S.; Seo, Y.; Rho, J.-R.; Cho, K.W.; Paul, V.J. New Bromotyrosine Metabolites from the Sponge Aplysinella rhax. Tetrahedron 2000, 56, 9071–9077. [Google Scholar] [CrossRef]
  109. Pina, I.C.; Gautschi, J.T.; Wang, G.Y.S.; Sanders, M.L.; Schmitz, F.J.; France, D.; Cornell-Kennon, S.; Sambucetti, L.C.; Remiszewski, S.W.; Perez, L.B.; et al. Psammaplins from the Sponge Pseudoceratina P Urpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase. J. Org. Chem. 2003, 68, 3866–3873. [Google Scholar] [CrossRef] [PubMed]
  110. Park, Y.; Liu, Y.; Hong, J.; Lee, C.O.; Cho, H.; Kim, D.K.; Im, K.S.; Jung, J.H. New Bromotyrosine Derivatives from an Association of Two Sponges, Jaspis W Ondoensis and Poecillastra W Ondoensis. J. Nat. Prod. 2003, 66, 1495–1498. [Google Scholar] [CrossRef] [PubMed]
  111. Yang, Q.; Liu, D.; Sun, D.; Yang, S.; Hu, G.; Wu, Z.; Zhao, L. Synthesis of the Marine Bromotyrosine Psammaplin F and Crystal Structure of a Psammaplin a Analogue. Molecules 2010, 15, 8784–8795. [Google Scholar] [CrossRef]
  112. Mujumdar, P.; Teruya, K.; Tonissen, K.F.; Vullo, D.; Supuran, C.T.; Peat, T.S.; Poulsen, S.A. An Unusual Natural Product Primary Sulfonamide: Synthesis, Carbonic Anhydrase Inhibition, and Protein X-Ray Structures of Psammaplin C. J. Med. Chem. 2016, 59, 5462–5470. [Google Scholar] [CrossRef]
  113. Kim, D.; Lee, I.S.; Jung, J.H.; Yang, S.I. Psammaplin a, a Natural Bromotyrosine Derivative from a Sponge, Possesses the Antibacterial Activity against Methicillin-Resistant Staphylococcus aureus and the DNA Gyrase-Inhibitory Activity. Arch. Pharmacal Res. 1999, 22, 25–29. [Google Scholar] [CrossRef]
  114. TTabudravu, J.; Eijsink, V.; Gooday, G.; Jaspars, M.; Komander, D.; Legg, M.; Synstad, B.; van Aalten, D. Psammaplin a, a Chitinase Inhibitor Isolated from the Fijian Marine Sponge Aplysinella rhax. Bioorganic Med. Chem. 2002, 10, 1123–1128. [Google Scholar] [CrossRef]
  115. Revelant, G.; Al-Lakkis-Wehbe, M.; Schmitt, M.; Alavi, S.; Schmitt, C.; Roux, L.; Al-Masri, M.; Schifano-Faux, N.; Maiereanu, C.; Tarnus, C.; et al. Exploring S1 Plasticity and Probing S1′ Subsite of Mammalian Aminopeptidase N/Cd13 with Highly Potent and Selective Aminobenzosuberone Inhibitors. Bioorganic Med. Chem. 2015, 23, 3192–3207. [Google Scholar] [CrossRef]
  116. Kim, T.H.; Kim, H.S.; Kang, Y.J.; Yoon, S.; Lee, J.; Choi, W.S.; Jung, J.H.; Kim, H.S. Psammaplin a Induces Sirtuin 1-Dependent Autophagic Cell Death in Doxorubicin-Resistant Mcf-7/Adr Human Breast Cancer Cells and Xenografts. Biochim. Biophys. Acta (BBA)-Gen. Subj. 2015, 1850, 401–410. [Google Scholar] [CrossRef]
  117. Ratovitski, E.A. Tumor Protein (Tp)-P53 Members as Regulators of Autophagy in Tumor Cells Upon Marine Drug Exposure. Mar. Drugs 2016, 14, 154. [Google Scholar] [CrossRef] [PubMed]
  118. Zhou, Y.-D.; Li, J.; Du, L.; Mahdi, F.; Le, T.P.; Chen, W.-L.; Swanson, S.M.; Watabe, K.; Nagle, D.G. Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins. Mar. Drugs 2018, 16, 442. [Google Scholar] [CrossRef] [PubMed]
  119. Ahn, M.Y.; Jung, J.H.; Na, Y.J.; Kim, H.S. A Natural Histone Deacetylase Inhibitor, Psammaplin a, Induces Cell Cycle Arrest and Apoptosis in Human Endometrial Cancer Cells. Gynecol. Oncol. 2008, 108, 27–33. [Google Scholar] [CrossRef] [PubMed]
  120. Kim, H.J.; Kim, J.H.; Chie, E.K.; Da Young, P.; Kim, I.A.; Kim, I.H. Dnmt (DNA Methyltransferase) Inhibitors Radiosensitize Human Cancer Cells by Suppressing DNA Repair Activity. Radiat. Oncol. 2012, 7, 1–10. [Google Scholar] [CrossRef]
  121. Kim, D.H.; Shin, J.; Kwon, H.J. Psammaplin a Is a Natural Prodrug That Inhibits Class I Histone Deacetylase. Exp. Mol. Med. 2007, 39, 47–55. [Google Scholar] [CrossRef]
  122. Jing, Q.; Hu, X.; Ma, Y.; Mu, J.; Liu, W.; Xu, F.; Li, Z.; Bai, J.; Hua, H.; Li, D. Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification. Mar. Drugs 2019, 17, 384. [Google Scholar] [CrossRef] [PubMed]
  123. Nicolaou, K.C.; Hughes, R.; Pfefferkorn, J.A.; Barluenga, S.; Roecker, A.J. Combinatorial Synthesis through Disulfide Exchange: Discovery of Potent Psammaplin a Type Antibacterial Agents Active against Methicillin-Resistant Staphylococcus aureus (MRSA). Chem. –A Eur. J. 2001, 7, 4280–4295. [Google Scholar] [CrossRef]
  124. Nicolaou, K.C.; Hughes, R.; Pfefferkorn, J.A.; Barluenga, S. Optimization and Mechanistic Studies of Psammaplin a Type Antibacterial Agents Active against Methicillin-Resistant Staphylococcus aureus (MRSA). Chem. –A Eur. J. 2001, 7, 4296–4310. [Google Scholar] [CrossRef]
  125. Alonso, I.P.; Sanchez, Y.M.A.; Ruiz, G.A.; González, M.L.R.; Hernández-Zanuy, A. Identificación De Actividad Inhibidora De Aminopeptidasa N Aislada De Riñón Porcino, En Invertebrados Marinos De La Plataforma Insular De La Habana/Identification of Porcine Kidney Aminopeptidase N Inhibitory Activity, in Marine Invertebrates from Havana Coastline. Rev. Cuba. Cienc. Biológicas 2016, 5, 15. [Google Scholar]
  126. Alonso, I.P.; Pedroso, A.; Sánchez, Y.M.A.; Valdés-Tresanco, M.E.; Méndez, L.R.; Fortun, S. La Aminopeptidasa a De Mamíferos: Características Bioquímicas, Funciones Fisiológicas Y Su Implicación En Procesos Fisiopatológicos En Humanos/Aminopeptidase a from Mammals: Biochemical Characteristics, Physiological Roles and Implication in Physiopathological Processes in Humans. Rev. Cuba. Cienc. Biológicas 2018, 6, 20. [Google Scholar]
  127. Göhring, B.; Holzhausen, H.; Meye, A.; Heynemann, H.; Rebmann, U.; Langner, J.; Riemann, D. Endopeptidase 24.11/Cd10 Is Down-Regulated in Renal Cell Cancer. Int. J. Mol. Med. 1998, 2, 409–423. [Google Scholar] [CrossRef] [PubMed]
  128. Tonna, S.; Dandapani, S.V.; Uscinski, A.; Appel, G.B.; Schlöndorff, J.S.; Zhang, K.; Denker, B.M.; Pollak, M.R. Functional Genetic Variation in Aminopeptidase a (Enpep): Lack of Clear Association with Focal and Segmental Glomerulosclerosis (Fsgs). Gene 2008, 410, 44–52. [Google Scholar] [CrossRef]
  129. del Carmen Puertas, M.; Martínez-Martos, J.M.; Cobo, M.; Lorite, P.; Sandalio, R.M.; Palomeque, T.; Torres, M.I.; Carrera-González, M.P.; Mayas, M.D.; Ramírez-Expósito, M.J. Plasma Renin–Angiotensin System-Regulating Aminopeptidase Activities Are Modified in Early Stage Alzheimer’s Disease and Show Gender Differences but Are Not Related to Apolipoprotein E Genotype. Exp. Gerontol. 2013, 48, 557–564. [Google Scholar] [CrossRef] [PubMed]
  130. Blanco, L.; Sanz, B.; Perez, I.; Sánchez, C.E.; Cándenas, M.L.; Pinto, F.M.; Gil, J.; Casis, L.; López, J.I.; Larrinaga, G. Altered Glutamyl-Aminopeptidase Activity and Expression in Renal Neoplasms. BMC Cancer 2014, 14, 386. [Google Scholar] [CrossRef]
  131. Bodineau, L.; Frugiere, A.; Marc, Y.; Inguimbert, N.; Fassot, C.; Balavoine, F.; Roques, B.; Llorens-Cortes, C. Orally Active Aminopeptidase a Inhibitors Reduce Blood Pressure: A New Strategy for Treating Hypertension. Hypertension 2008, 51, 1318–1325. [Google Scholar] [CrossRef] [PubMed]
  132. Matsui, M.; Fowler, J.H.; Walling, L.L. Leucine Aminopeptidases: Diversity in Structure and Function. Biol. Chem. 2006, 387, 1535–1544. [Google Scholar] [CrossRef] [PubMed]
  133. Scranton, M.A.; Yee, A.; Park, S.-Y.; Walling, L.L. Plant Leucine Aminopeptidases Moonlight as Molecular Chaperones to Alleviate Stress-Induced Damage. J. Biol. Chem. 2012, 287, 18408–18417. [Google Scholar] [CrossRef]
  134. Chao, W.S.; Gu, Y.-Q.; Pautot, V.; Bray, E.A.; Walling, L.L. Leucine Aminopeptidase Rnas, Proteins, and Activities Increase in Response to Water Deficit, Salinity, and the Wound Signals Systemin, Methyl Jasmonate, and Abscisic Acid. Plant Physiol. 1999, 120, 979–992. [Google Scholar] [CrossRef]
  135. Alén, C.; Sherratt, D.J.; Colloms, S. Direct Interaction of Aminopeptidase a with Recombination Site DNA in Xer Site-Specific Recombination. EMBO J. 1997, 16, 5188–5197. [Google Scholar] [CrossRef]
  136. Behari, J.; Stagon, L.; Calderwood, S.B. Pepa, a Gene Mediating Ph Regulation of Virulence Genes in Vibrio cholerae. J. Bacteriol. 2001, 183, 178–188. [Google Scholar] [CrossRef]
  137. Aly, A.S.; Vaughan, A.M.; Kappe, S.H. Malaria Parasite Development in the Mosquito and Infection of the Mammalian Host. Annu. Rev. Microbiol. 2009, 63, 195–221. [Google Scholar] [CrossRef] [PubMed]
  138. Goldberg, D.E. Complex Nature of Malaria Parasite Hemoglobin Degradation. Proc. Natl. Acad. Sci. USA 2013, 110, 5283–5284. [Google Scholar] [CrossRef] [PubMed]
  139. Skinner-Adams, T.S.; Stack, C.M.; Trenholme, K.R.; Brown, C.L.; Grembecka, J.; Lowther, J.; Mucha, A.; Drag, M.; Kafarski, P.; McGowan, S.; et al. Plasmodium falciparum Neutral Aminopeptidases: New Targets for Anti-Malarials. Trends Biochem. Sci. 2010, 35, 53–61. [Google Scholar] [CrossRef] [PubMed]
  140. Calic, P.P.; Vinh, N.B.; Webb, C.T.; Malcolm, T.R.; Ngo, A.; Lowes, K.; Drinkwater, N.; McGowan, S.; Scammells, P.J. Structure-Based Development of Potent Plasmodium Falciparum M1 and M17 Aminopeptidase Selective and Dual Inhibitors Via S1’-Region Optimisation. Eur. J. Med. Chem. 2023, 248, 115051. [Google Scholar] [CrossRef] [PubMed]
  141. Drinkwater, N.; Vinh, N.B.; Mistry, S.N.; Bamert, R.S.; Ruggeri, C.; Holleran, J.P.; Loganathan, S.; Paiardini, A.; Charman, S.A.; Powell, A.K.; et al. Potent Dual Inhibitors of Plasmodium falciparum M1 and M17 Aminopeptidases through Optimization of S1 Pocket Interactions. Eur. J. Med. Chem. 2016, 110, 43–64. [Google Scholar] [CrossRef]
  142. Bauvois, B.; Dauzonne, D. Aminopeptidase-N/Cd13 (Ec 3.4. 11.2) Inhibitors: Chemistry, Biological Evaluations, and Therapeutic Prospects. Med. Res. Rev. 2006, 26, 88–130. [Google Scholar] [CrossRef]
  143. Kancharla, P.; Li, Y.; Yeluguri, M.; Dodean, R.A.; Reynolds, K.A.; Kelly, J.X. Total Synthesis and Antimalarial Activity of 2-(P-Hydroxybenzyl)-Prodigiosins, Isoheptylprodigiosin, and Geometric Isomers of Tambjamine Myp1 Isolated from Marine Bacteria. J. Med. Chem. 2021, 64, 8739–8754. [Google Scholar] [CrossRef]
  144. Nweze, J.A.; Mbaoji, F.N.; Li, Y.-M.; Yang, L.-Y.; Huang, S.-S.; Chigor, V.N.; Eze, E.A.; Pan, L.-X.; Zhang, T.; Yang, D.-F. Potentials of Marine Natural Products against Malaria, Leishmaniasis, and Trypanosomiasis Parasites: A Review of Recent Articles. Infect. Dis. Poverty 2021, 10, 1–19. [Google Scholar] [CrossRef]
  145. Zayed, A.; Negm, W.; Kabbash, A.; Ezzat, S.M. Marine-Derived Metabolites as Antimalarial Candidates Targeting Various Life Stages. J. Adv. Med. Pharm. Res. 2022, 3, 12–18. [Google Scholar] [CrossRef]
  146. Singh, H.; Parida, A.; Debbarma, K.; Ray, D.P.; Banerjee, P. Common Marine Organisms: A Novel Source of Medicinal Compounds. Int. J. Bioresour. Sci. 2020, 7, 39–49. [Google Scholar] [CrossRef]
  147. Zhang, M.; Tian, Z.; Wang, J.; Tian, X.; Wang, C.; Cui, J.; Huo, X.; Feng, L.; Yu, Z.; Ma, X. Visual Analysis and Inhibitor Screening of Leucine Aminopeptidase, a Key Virulence Factor for Pathogenic Bacteria-Associated Infection. ACS Sens. 2021, 6, 3604–3610. [Google Scholar] [CrossRef] [PubMed]
  148. Fang, C.; Zhang, J.; Yang, H.; Peng, L.; Wang, K.; Wang, Y.; Zhao, X.; Liu, H.; Dou, C.; Shi, L.; et al. Leucine Aminopeptidase 3 Promotes Migration and Invasion of Breast Cancer Cells through Upregulation of Fascin and Matrix Metalloproteinases-2/9 Expression. J. Cell. Biochem. 2019, 120, 3611–3620. [Google Scholar] [CrossRef] [PubMed]
  149. Yang, H.; Dai, G.; Wang, S.; Zhao, Y.; Wang, X.; Zhao, X.; Zhang, H.; Wei, L.; Zhang, L.; Guo, S.; et al. Inhibition of the Proliferation, Migration, and Invasion of Human Breast Cancer Cells by Leucine Aminopeptidase 3 Inhibitors Derived from Natural Marine Products. Anti-Cancer Drugs 2020, 31, 60–66. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 21 00279 g001 550
Figure 1. Cartoon representation of the 3D structure of the three aminopeptidases focused on by the present contribution: (A) human aminopeptidase N (PDB ID: 4fyq), (B) human aminopeptidase A (PDB ID: 4kx7), and (C) Plasmodium falciparum M17 aminopeptidase PfA-M17 (PDB ID: 4r76). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Figure 1. Cartoon representation of the 3D structure of the three aminopeptidases focused on by the present contribution: (A) human aminopeptidase N (PDB ID: 4fyq), (B) human aminopeptidase A (PDB ID: 4kx7), and (C) Plasmodium falciparum M17 aminopeptidase PfA-M17 (PDB ID: 4r76). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Marinedrugs 21 00279 g001
Marinedrugs 21 00279 g002 550
Figure 2. Structures of low molecular weight non-peptidic protease inhibitors of different mechanistic classes isolated from marine organisms. Serine peptidase inhibitors: (A) cicloteonamide A [56], (B) general structure of cicloteonamide E [56], (C) aeruginosine 298-A, (D) dinosine, (E) oscilarina [57]; cystein peptidase inhibitors: (F) tokaramida A [45], (G) discorhabdina P [58], (H) secobatzellina A [59]; aspartic peptidases inhibitors: (I) N,N-dimetiltiocarbamate, (J) 6 Br-aplisinopsine [60]; metalloendopeptidase inhibitors: (K) jaspisin [43], (L) 1-12-hidroxioctadecanil sodium sulphate [61], (M) calisponginol sulphate [46], (N) Ageladine A [47], (O) Eckol [62].
Figure 2. Structures of low molecular weight non-peptidic protease inhibitors of different mechanistic classes isolated from marine organisms. Serine peptidase inhibitors: (A) cicloteonamide A [56], (B) general structure of cicloteonamide E [56], (C) aeruginosine 298-A, (D) dinosine, (E) oscilarina [57]; cystein peptidase inhibitors: (F) tokaramida A [45], (G) discorhabdina P [58], (H) secobatzellina A [59]; aspartic peptidases inhibitors: (I) N,N-dimetiltiocarbamate, (J) 6 Br-aplisinopsine [60]; metalloendopeptidase inhibitors: (K) jaspisin [43], (L) 1-12-hidroxioctadecanil sodium sulphate [61], (M) calisponginol sulphate [46], (N) Ageladine A [47], (O) Eckol [62].
Marinedrugs 21 00279 g002
Marinedrugs 21 00279 g003 550
Figure 3. Structures of inhibitors isolated from marine invertebrates in complex with target proteases. (A) ShPI-1 isolated from the sea anemone Stichodactyla helianthus in complex with bovine trypsin (PDB ID: 3m7q), (B) ShPI-1 in complex with bovine chymotrypsin (PDB ID: 3t62), (C) ShPI-1 in complex with pancreatic elastase, and (PDB ID: 3m7Q), (D) SmCI isolated from marine annelide Sabellastarte magnifica in complex with human carboxypeptidase A4 (hCPA4) [51]. Residues interacting with the S1 subsite have been highlighted as sticks. Proteases and inhibitors are colored cyan and orange, respectively. The zinc atom in hCPA4 is shown as a gray sphere.
Figure 3. Structures of inhibitors isolated from marine invertebrates in complex with target proteases. (A) ShPI-1 isolated from the sea anemone Stichodactyla helianthus in complex with bovine trypsin (PDB ID: 3m7q), (B) ShPI-1 in complex with bovine chymotrypsin (PDB ID: 3t62), (C) ShPI-1 in complex with pancreatic elastase, and (PDB ID: 3m7Q), (D) SmCI isolated from marine annelide Sabellastarte magnifica in complex with human carboxypeptidase A4 (hCPA4) [51]. Residues interacting with the S1 subsite have been highlighted as sticks. Proteases and inhibitors are colored cyan and orange, respectively. The zinc atom in hCPA4 is shown as a gray sphere.
Marinedrugs 21 00279 g003
Marinedrugs 21 00279 g004 550
Figure 4. Structure of CmPI-II (a serine protease inhibitor isolated from the marine snail Cenchritis muricatus). (A) Family of the 15 lowest energy structures of CmPI-II obtained by NMR. (B) Ribbons-like representation of the lowest energy structure. The β strands (β1–β3) and the α helix are represented in red and blue, respectively. Orange parts represent the hydrophobic nucleus of the protein and green shows disulfide bridges. (C) Prediction of the 3D structure of the CmPI-II/subtilisin A complex. CmPI-II is shown in red and subtilisin A in blue [53]. Courtesy of Prof. Aymara Cabrera Muñoz.
Figure 4. Structure of CmPI-II (a serine protease inhibitor isolated from the marine snail Cenchritis muricatus). (A) Family of the 15 lowest energy structures of CmPI-II obtained by NMR. (B) Ribbons-like representation of the lowest energy structure. The β strands (β1–β3) and the α helix are represented in red and blue, respectively. Orange parts represent the hydrophobic nucleus of the protein and green shows disulfide bridges. (C) Prediction of the 3D structure of the CmPI-II/subtilisin A complex. CmPI-II is shown in red and subtilisin A in blue [53]. Courtesy of Prof. Aymara Cabrera Muñoz.
Marinedrugs 21 00279 g004
Marinedrugs 21 00279 g005 550
Figure 5. Uniprot alignment of the aminoacidic sequence of the active site of various M1 family aminopeptidases: AMPE_Human: human aminopeptidase E, AMPN_Human: human aminopeptidase N, AMPN_Pig: porcine aminopeptidase N, ERAP1_Human: endoplasmatic reticulum aminopeptidase 1, LCAP_Human: human leucyl-cystinyl aminopeptidase, LKHA4_Human: human leukotriene A4 hydrolase, PSA_Human: human puromycin sensitive aminopeptidase, AMPB_Human: human aminopeptidase B, AMPO_Human: human aminopeptidase O, TRHDE_Human: human thyrotrophin-releasing hormone-degrading enzyme or pyroglutamyl aminopeptidase II, AMPQ_Human: human aminopeptidase Q, AMPQ_Mouse: mouse aminopeptidase Q. On the right of each sequence, the access number and identifiers from Uniprot are included. The short name for each enzyme corresponds to Uniprot abbreviations. The rectangle A encircles the conserved sequence GAMEN related with the aminopeptidase activities of these enzymes from M1 family, and the rectangle B encircles the consensus sequences HEXXH from the active site. Signs below alignment points to other highly conserved amino acid residues inside the M1 family. * indicates residues completely conserved, : indicates position with high degree of conservation of the residues, and . indicates position with mild degree of conservation of the residues.
Figure 5. Uniprot alignment of the aminoacidic sequence of the active site of various M1 family aminopeptidases: AMPE_Human: human aminopeptidase E, AMPN_Human: human aminopeptidase N, AMPN_Pig: porcine aminopeptidase N, ERAP1_Human: endoplasmatic reticulum aminopeptidase 1, LCAP_Human: human leucyl-cystinyl aminopeptidase, LKHA4_Human: human leukotriene A4 hydrolase, PSA_Human: human puromycin sensitive aminopeptidase, AMPB_Human: human aminopeptidase B, AMPO_Human: human aminopeptidase O, TRHDE_Human: human thyrotrophin-releasing hormone-degrading enzyme or pyroglutamyl aminopeptidase II, AMPQ_Human: human aminopeptidase Q, AMPQ_Mouse: mouse aminopeptidase Q. On the right of each sequence, the access number and identifiers from Uniprot are included. The short name for each enzyme corresponds to Uniprot abbreviations. The rectangle A encircles the conserved sequence GAMEN related with the aminopeptidase activities of these enzymes from M1 family, and the rectangle B encircles the consensus sequences HEXXH from the active site. Signs below alignment points to other highly conserved amino acid residues inside the M1 family. * indicates residues completely conserved, : indicates position with high degree of conservation of the residues, and . indicates position with mild degree of conservation of the residues.
Marinedrugs 21 00279 g005
Marinedrugs 21 00279 g006 550
Figure 6. Cartoon representation of different M1 family aminopeptidases: (A) pepN from Escherichia coli (PDB ID: 2dq6), (B) Plasmodium falciparum aminopeptidase N PfA-M1 (PDB ID: 3ebh), (C) human ERAP 1 (PDB ID: 3mdj), (D) human ERAP 2 (PDB ID: 3se6), (E) human leukotriene A4 hydrolase (PDB ID: 1hs6), (F) Saccharomyces cerevisiae leukotriene A4 hydrolase (PDB ID: 2xq0), (G) Thermoplasma acidophilum tricorn interacting factor F3 (PDB ID: 1z1w), (H) Colwellia psychrerythraea cold-active aminopeptidase (PDB ID: 3cia). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Figure 6. Cartoon representation of different M1 family aminopeptidases: (A) pepN from Escherichia coli (PDB ID: 2dq6), (B) Plasmodium falciparum aminopeptidase N PfA-M1 (PDB ID: 3ebh), (C) human ERAP 1 (PDB ID: 3mdj), (D) human ERAP 2 (PDB ID: 3se6), (E) human leukotriene A4 hydrolase (PDB ID: 1hs6), (F) Saccharomyces cerevisiae leukotriene A4 hydrolase (PDB ID: 2xq0), (G) Thermoplasma acidophilum tricorn interacting factor F3 (PDB ID: 1z1w), (H) Colwellia psychrerythraea cold-active aminopeptidase (PDB ID: 3cia). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Marinedrugs 21 00279 g006
Marinedrugs 21 00279 g007 550
Figure 7. Potential therapeutic applications of targeting central TRH-degrading ectoenzyme activity.
Figure 7. Potential therapeutic applications of targeting central TRH-degrading ectoenzyme activity.
Marinedrugs 21 00279 g007
Marinedrugs 21 00279 g008 550
Figure 8. Some of the marine organisms screened for inhibitory activity of TRH-DE and DPP-IV. (A) Hermodice carunculata, (B) Palythoa caribaeorum, (C) Condylactis gigantea, and (D) Stichodactyla helianthus. Pictures courtesy of Professor José Espinosa, PhD, ICIMAR, CITMA, Cuba.
Figure 8. Some of the marine organisms screened for inhibitory activity of TRH-DE and DPP-IV. (A) Hermodice carunculata, (B) Palythoa caribaeorum, (C) Condylactis gigantea, and (D) Stichodactyla helianthus. Pictures courtesy of Professor José Espinosa, PhD, ICIMAR, CITMA, Cuba.
Marinedrugs 21 00279 g008
Marinedrugs 21 00279 g009 550
Figure 9. TRH-DE inhibition by HcPI in different enzyme models. (A) Ki determination of HcPI effect on TRH-DE activity in rat brain membranes, (B) inhibition effect of HcPI on TRH-DE activity in primary cultures of rat adepnohypophysis, and (C) effect of intraperitoneal injection of different doses of HcPI on mouse TRH-DE specific activity in brain [49]; Different letters indicate a significant difference between treatment groups, with p < 0.001.
Figure 9. TRH-DE inhibition by HcPI in different enzyme models. (A) Ki determination of HcPI effect on TRH-DE activity in rat brain membranes, (B) inhibition effect of HcPI on TRH-DE activity in primary cultures of rat adepnohypophysis, and (C) effect of intraperitoneal injection of different doses of HcPI on mouse TRH-DE specific activity in brain [49]; Different letters indicate a significant difference between treatment groups, with p < 0.001.
Marinedrugs 21 00279 g009
Marinedrugs 21 00279 g010 550
Figure 10. Functions of human APN/CD13 (adapted from Amin et al. [19]).
Figure 10. Functions of human APN/CD13 (adapted from Amin et al. [19]).
Marinedrugs 21 00279 g010
Marinedrugs 21 00279 g011 550
Figure 11. Up-regulation of human APN in different cancers. Abbreviations: renal cell cancer (RCC), hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC), non-small-cell lung carcinoma (NSCLC).
Figure 11. Up-regulation of human APN in different cancers. Abbreviations: renal cell cancer (RCC), hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC), non-small-cell lung carcinoma (NSCLC).
Marinedrugs 21 00279 g011
Marinedrugs 21 00279 g012 550
Figure 12. Natural inhibitors of Aminopeptidase N.
Figure 12. Natural inhibitors of Aminopeptidase N.
Marinedrugs 21 00279 g012
Marinedrugs 21 00279 g013 550
Figure 13. The chemical structure of psammaplin compounds, biprasin, and aplysinellin A.
Figure 13. The chemical structure of psammaplin compounds, biprasin, and aplysinellin A.
Marinedrugs 21 00279 g013
Marinedrugs 21 00279 g014 550
Figure 14. Examples of synthetic homo- and hetero-derivatives of psammaplin A. The blue dashed line box highlights derivatives that showed significant antibacterial effects against methicillin-resistant Staphylococcus aureus (MRSA) due to DNA gyrase inhibition and bacterial DNA synthesis arrest. The red dashed line box highlights derivatives that showed higher antibacterial activity than psammaplin A. The green dashed line box highlights a derivative that showed similar antibacterial activity to clinically used drugs vancomycin and ciprofloxacin. The yellow dashed line box highlights derivatives that possessed 50-fold higher activities than psammaplin A vs. Staphylococcus aureus and MRSA, in this case mainly by a nonspecific redox-based mechanism (reviewed in [122]).
Figure 14. Examples of synthetic homo- and hetero-derivatives of psammaplin A. The blue dashed line box highlights derivatives that showed significant antibacterial effects against methicillin-resistant Staphylococcus aureus (MRSA) due to DNA gyrase inhibition and bacterial DNA synthesis arrest. The red dashed line box highlights derivatives that showed higher antibacterial activity than psammaplin A. The green dashed line box highlights a derivative that showed similar antibacterial activity to clinically used drugs vancomycin and ciprofloxacin. The yellow dashed line box highlights derivatives that possessed 50-fold higher activities than psammaplin A vs. Staphylococcus aureus and MRSA, in this case mainly by a nonspecific redox-based mechanism (reviewed in [122]).
Marinedrugs 21 00279 g014
Marinedrugs 21 00279 g015 550
Figure 15. Some of the marine invertebrates screened for inhibitory activity of porcine APN. (A) Eucidiaris tribuloides, (B) Ophiocoma echinata, (C) Lebrunia danae, (D) Ascidia sydneiensis, (E) Esteinacidia turbinata, and (F) Phallusia nigra. Pictures courtesy of Professor José Espinosa, PhD from ICIMAR, CITMA, Cuba.
Figure 15. Some of the marine invertebrates screened for inhibitory activity of porcine APN. (A) Eucidiaris tribuloides, (B) Ophiocoma echinata, (C) Lebrunia danae, (D) Ascidia sydneiensis, (E) Esteinacidia turbinata, and (F) Phallusia nigra. Pictures courtesy of Professor José Espinosa, PhD from ICIMAR, CITMA, Cuba.
Marinedrugs 21 00279 g015
Marinedrugs 21 00279 g016 550
Figure 16. Some of the marine invertebrates which show inhibitory activity of pAPN, pAPA, hAPN, and rPfA-M17. (A) Cenchritis muricatus, (B) Nerita versicolor, (C) Lissodendoryx (Lissodendoryx) isodictyalis, (D) Tripneustes ventricosus, (E) Echinaster (Othilia) echinophorus, (F) Isostichopus badionotus, (G) Stichodactyla helianthus, and (H) Bunodosoma granuliferum. Pictures courtesy of Professor José Espinosa, PhD from ICIMAR, CITMA, Cuba.
Figure 16. Some of the marine invertebrates which show inhibitory activity of pAPN, pAPA, hAPN, and rPfA-M17. (A) Cenchritis muricatus, (B) Nerita versicolor, (C) Lissodendoryx (Lissodendoryx) isodictyalis, (D) Tripneustes ventricosus, (E) Echinaster (Othilia) echinophorus, (F) Isostichopus badionotus, (G) Stichodactyla helianthus, and (H) Bunodosoma granuliferum. Pictures courtesy of Professor José Espinosa, PhD from ICIMAR, CITMA, Cuba.
Marinedrugs 21 00279 g016
Marinedrugs 21 00279 g017 550
Figure 17. Role of aminopeptidase A and aminopeptidase N in the renin–angiotensin systems.
Figure 17. Role of aminopeptidase A and aminopeptidase N in the renin–angiotensin systems.
Marinedrugs 21 00279 g017
Marinedrugs 21 00279 g018 550
Figure 18. Functions of M17 aminopeptidases from different life groups.
Figure 18. Functions of M17 aminopeptidases from different life groups.
Marinedrugs 21 00279 g018
Marinedrugs 21 00279 g019 550
Figure 19. Cartoon representation of different M17 family aminopeptidases: (A) Bos taurus leucyl aminopeptidase 3 (PDB ID: 1bll), (B) Escherichia coli PepA aminopeptidase (PDB ID: 1gyt), and (C) ZK353.6 (Caenorhabditis elegans) (PDB ID: 42hc9). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Figure 19. Cartoon representation of different M17 family aminopeptidases: (A) Bos taurus leucyl aminopeptidase 3 (PDB ID: 1bll), (B) Escherichia coli PepA aminopeptidase (PDB ID: 1gyt), and (C) ZK353.6 (Caenorhabditis elegans) (PDB ID: 42hc9). Colors: alpha-helices (cyan), beta sheets (warm pink), and loops (salmon). The zinc atoms are shown as gray spheres highlighted in a yellow box.
Marinedrugs 21 00279 g019
Marinedrugs 21 00279 g020 550
Figure 20. Examples of natural inhibitors of M17 enzymes.
Figure 20. Examples of natural inhibitors of M17 enzymes.
Marinedrugs 21 00279 g020
Marinedrugs 21 00279 g021 550
Figure 21. Compounds 5 and 6 as new inhibitors of LAP3 (adapted from Yang et al. [149]).
Figure 21. Compounds 5 and 6 as new inhibitors of LAP3 (adapted from Yang et al. [149]).
Marinedrugs 21 00279 g021
Table
Table 1. Some members of the M1 family of the MA(E) subclan of metallopeptidases. (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 9 January 2023).
Table 1. Some members of the M1 family of the MA(E) subclan of metallopeptidases. (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 9 January 2023).
EnzymeIUBMB *
Nomenclature		Merops IDSources
Aminopeptidase N (APN)EC 3.4.11.2M01.001Homo sapiens, Sus scrofa
Lysyl aminopeptidase-M01.002Escherichia coli
Aminopeptidase A (APA)EC 3.4.11.7M01.003Homo sapiens
Leukotriene A4 hydrolase (LTA4H)EC 3.3.2.6M01.004Homo sapiens
Alanyl aminopeptidase (bacterial-type)EC 3.4.11.2M01.005Escherichia coli, Arabidopsis thaliana
Ape2 aminopeptidase-M01.006Saccharomyces cerevisiae
Aap1’ aminopeptidase-M01.007Saccharomyces cerevisiae
Thyrotropin-releasing hormone-degrading ectoenzyme or Pyroglutamyl-peptidase II (TRH-DE, PPII)EC 3.4.19.6M01.008Homo sapiens, Mus musculus, Ratus novergicus
Aminopeptidase N (actinomycete-type)-M01.009Streptomyces lividans
Cytosol alanyl aminopeptidase-M01.010Homo sapiens, Arabidopsis thaliana, Caenorhabditis elegans
Insulin-regulated membrane aminopeptidase or cystinyl Aminopeptidase (IRAP)EC 3.4.11.3M01.011Homo sapiens
Aminopeptidase G-M01.012Streptomyces coelicolor
Aminopeptidase N (insect)-M01.013Manduca sexta
Aminopeptidase B (APB)EC 3.4.11.6M01.014Homo sapiens
Aminopeptidase H11 (nematode)-M01.015
Aminopeptidase EyEC 3.4.11.20M01.016Gallus gallus domesticus
TMA108 protein-M01.017Saccharomyces cerevisiae
Endoplasmic reticulum aminopeptidase 1 ERAP-1-M01.018Homo sapiens
Tricorn interacting factor F2-M01.020Thermoplasma acidophilum
Tricorn interacting factor F3-M01.021Thermoplasma acidophilum
Arginyl aminopeptidase-like 1-M01.022Homo sapiens
Endoplasmic reticulum aminopeptidase 2 ERAP-2-M01.024Homo sapiens
Aminopeptidase-1 (Caenorhabditis-type)-M01.025Caenorhabditis elegans
Aminopeptidase Q-M01.026Homo sapiens
Aminopeptidase O (AP-O)EC 3.4.11.-M01.028Homo sapiens
M1 aminopeptidase (Plasmodium spp.)EC 3.4.11.2M01.029Plasmodium falciparum
Aminopeptidase N2 (insect)-M01.030Manduca sexta
Cold-active aminopeptidase (Colwellia psychrerythraea)-Type peptidase-M01.031Colwellia psychrerythraea
Lysyl aminopeptidase 1 (Streptomyces sp.)-M01.032Streptomyces albulus
Lysyl endopeptidase (Streptomyces albulus)-M01.033Streptomyces albulus
Leukotriene A4 hydrolase (Saccharomyces cerevisiae)EC 3.3.2.6M01.034Saccharomyces cerevisiae
LePepA g.p. (Legionella pneumophila)-M01.035Legionella pneumophila
* IUBMB: International Union of Biochemistry and Molecular Biology.
Table
Table 2. Crystallographic structures reported for members of the M1 family of metallopeptidases (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 10 January 2023).
Table 2. Crystallographic structures reported for members of the M1 family of metallopeptidases (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 10 January 2023).
EnzymeSourceCrystallographic Codes of the Structures at Protein Data Bank (PDB)
aminopeptidase NPlasmodium falciparum3EBG, 3EBH, 3EBI, 3Q43, 3Q44, 3T8V, 4J3B, 4K5L, 4K5M, 4K5N, 4K5O,4K5P, 4R5T, 4R5V, 4R5X, 4ZQT, 4ZW3, 4ZW5, 4ZW6, 4ZW7, 4ZW8, 4ZX3, 4ZX4, 4ZX5, 4ZX6, 5XM7, 5Y19, 5Y1H, 5Y1K, 5Y1Q, 5Y1R, 5Y1S, 5Y1T, 5Y1V, 5Y1W, 5Y1X, 6EA1, 6EA2, 6EAA, 6EAB, 6EE3, 6EE4, 6EE6, 6EED, 6SBQ, 6SBR
aminopeptidase NEscherichia coli2DQ6, 2DQM, 2HPO, 2HPT, 2ZXG, 3B2P, 3B2X, 3B34, 3B37, 3B3B, 3KED, 3PUU, 3QJX,4Q4E, 4Q4I, 4XMT, 4XMU, 4XMV, 4XMW, 4XMX, 4XM2, 4XN1, 4XN2, 4XN4, 4XN5, 4XN7, 4XN8, 4XN9, 4XNA, 4XNB, 4XND, 4X03, 4X04, 4X05, 5MFR, 5MFS, 5MFT, 5Y01, 5YQ1, 5YQ2, 5YQB, 6G8B
aminopeptidase NHomo sapiens4FYQ, 4FYR, 4FYS, 4FYT, 5LHD, 6AKT
aminopeptidase NSus scrofa4FSC, 4FKE, 4FKH, 4FKK, 4HOM, 4NAQ, 4NZ8, 4OU3
ERAP 1Homo sapiens2XDT, 2YD0, 3MDJ, 3QNF, 3RJO, 6Q4R
ERAP 2Homo sapiens3SE6, 4E36, 4JBS, 5AB0, 5AB2, 5CU5, 5J6S, 5KIV
aminopeptidase AHomo sapiens4KX7, 4KX8, 4KX9, 4KXA, 4KXB, 4KXC, 4KXD
leukotriene A4 hydrolaseHomo sapiens1G6W, 1H19, 1HS6, 1SQM, 2R59, 2VJ8, 3B7R, 3B7S, 3B7T, 3B7U, 3CHO, 3CHP, 3CHQ, 3CHR, 3CHS, 3FH5, 3FH7, 3FH8, 3FHE, 3FTS, 3FTU, 3FTV, 3FTW, 3FTX, 3FTY, 3FTZ, 3FU0, 3FU3, 3FU5, 3FU6, 3FUD, 3FUE, 3FUF, 3FUH, 3FUI, 3FUJ, 3FUK, 3FUL, 3FUM, 3FUN, 3U9W, 4DPR, 4L2L, 4MKT, 4Ms6, 4RSY, 4RVB, 5AEN, 5BPP, 5FWQ, 5N3W, 5NI2, 5NI4, 5NI6, 5NIA, 5NID, 5NIE, 6ENB, 6ENC, 6END
leukotriene A4 hydrolase
(Saccharomyces cerevisiae)		Saccharomyces cerevisiae (ATCC 204508/S288c)2XPY, 2XPZ, 2XQ0
cold-active aminopeptidase (Colwellia psychrerythraea)-type peptidaseColwellia psychrerythraea (34H/ATCC BAA-681)3CIA
tricorn interacting factor F3Thermoplasma acidophilum (ATCC 25905/DSM 1728/JCM 9062/NBRC 15155/AMRC-C165)1Z1W,1Z5H, 3Q7J
LePepA g.p. (Legionella pneumophila)Legionella pneumophila5ZI5, 5ZI7, 5ZIE
TATA-binding protein-associated factorHomo sapiens5FUR, 6MZC, 6MZL, 6MZM
IRAP (cystinil aminopeptidase)Homo sapiens4P8Q, 4PJ6, 4Z7I, 5C97, 5MJ6
Table
Table 3. Screening of inhibitory activity of TRH-DE and DPP-IV in aqueous extracts from marine invertebrates collected at the Havana coastline, Cuba (adapted from Pascual et al. [49]).
Table 3. Screening of inhibitory activity of TRH-DE and DPP-IV in aqueous extracts from marine invertebrates collected at the Havana coastline, Cuba (adapted from Pascual et al. [49]).
SpeciesPhylum[Protein] Crude Extract (mg/mL)Inhibit Activity of DPP-IV (U/mg)Inhibit Activity of TRH-DE (U/mg)
Caulerpa racemosaChlorophyta5.86--
Dictyosphaeria cavernosaChlorophycota8.73--
Halimeda opuntiaChlorophycota14.72--
Halimeda incrassataChlorophycota10.23--
Bidens pilosaMagnoliophyta22.78--
Ascidia sidneyenseChordata57.27--
Molgula occidentalisChordata31.41--
Pyura vittataChordata58.53--
Phallusia nigraChordata25.9093.00-
Microcosmus gamusChordata24.45--
Tectitethya criptaPorifera0.90--
Mycale microsigmatosaPorifera43.5056.59-
Lima scabraMollusca51.55--
Aplisia dactilomelaMollusca24.00--
Zoanthus pullchelusCnidaria15.57--
Plexaura homomallaCnidaria15.25--
Condylactis giganteaCnidaria36.6079.46-
Stichodactyla helianthusCnidaria79.5017.48-
Cassiopea xamachanaCnidaria3.14--
Physalia physalisCnidaria13.84--
Palythoa caribaeorumCnidaria16.80133.00-
Bartholomea annulataCnidaria56.50 -
Hermodice carunculataAnnelida62.41- 24.00
Sabellastarte magnificaAnnelida67.24--
Holothuria floridianaEchinodermata18.84--
Holothuria mexicanaEchinodermata29.63--
Table
Table 4. Summary of the preliminary characterization of the porcine APN inhibitory activity detected in crude extracts of marine invertebrate species (screening in the period 2011–2015) (adapted from Pascual et al. [125]).
Table 4. Summary of the preliminary characterization of the porcine APN inhibitory activity detected in crude extracts of marine invertebrate species (screening in the period 2011–2015) (adapted from Pascual et al. [125]).
SpeciesPhylumpAPN Inhibitory Activity
(U/mL)		pAPN Specific Inhibitory Activity
(U/mg)		Pre-Incubation Time (min)IC50 (mg/mL)
Phallusia nigraChordata2.30600.8363--
Lisoclinum verrilliChordata7.87700.736110.11 ± 0.06
Ascidia sidneyensisChordata3.17600.6481--
Microcosmus guanusChordata7.13680.5366--
Esteinacidia turbinataChordata3.63400.5344--
Diplosoma listerianumChordata8.13000.4394300.11 ± 0.26
Poticlenum constellatumChordata3.22300.2984--
Eucidaris tribuloidesEchinodermata6.25260.320651.35 ± 0.19
Ophiocoma echinataEchinodermata8.23370.0874602.39 ± 1.09
Lebrunia danaeEchinodermata----
Bryozoo sp1Bryozoa5.72400.0560--
Bryozoo sp2Bryozoa6.76001.1266300.29 ± 0.05
Hermodice carunculataAnnelida----
Table
Table 5. Summary of the screening of phyla Mollusca, Poriphera, Echinodermata, and Cnidaria for inhibitory activity against human APN (hAPN) (see note below). Adapted from [98].
Table 5. Summary of the screening of phyla Mollusca, Poriphera, Echinodermata, and Cnidaria for inhibitory activity against human APN (hAPN) (see note below). Adapted from [98].
SpeciesPhylumNA-like Activity
(×104 U/mg)		Crude Extracts hAPN sIA (U/mg)2.5% TCA Treated Extracts hAPN sIA (U/mg)
Cenchritis muricatusMolluscaND0.465.20
Nerita pelorontaMollusca6.95 ± 2.84ND5.06
Nerita versicolorMollusca12.56 ± 1.70ND2.21
Lissodendoryx (Lissodendoryx) isodictyalisPorifera1.51 ± 0.49ND171.92
Tripneustes ventricosusEchinodermata6.39 ± 0.07ND56.86
Echinaster (Othilia) echinophorusEchinodermata58.87 ± 12.62ND10.82
Isostichopus badionotusEchinodermataND1.5633.81
Stichodactyla helianthusCnidaria9.63 ± 2.68ND32.81
Bunodosoma granuliferumCnidaria39.44 ± 5.45ND4.31
Physalia physalisCnidaria2.04 ± 0.52ND13.13
NOTE: hAPN inhibitory activities in aqueous crude and 2.5% TCA extracts are expressed as specific Inhibitory Activity (sIA) in U/mg. One unit of enzyme activity was defined as the amount of enzyme needed to produce one arbitrary unit of fluorescence per minute, and inhibitory activities are expressed per mg of extract. The first column indicates tested species, the second column shows neutral aminopeptidase-like activity (NA) detected in aqueous crude extracts using L-Leu-AMC as substrate, and the remaining columns refer to sIA. (ND): not detected.
Table
Table 6. Summary of the preliminary characterization of inhibitory activities against porcine APA, porcine APN, and human APN in TCA 2.5% treated crude extracts from marine invertebrates (screening in the period 2015–2019). Effect on 3LL and PC3 tumor cell viability (adapted from [98]). ND: not determined.
Table 6. Summary of the preliminary characterization of inhibitory activities against porcine APA, porcine APN, and human APN in TCA 2.5% treated crude extracts from marine invertebrates (screening in the period 2015–2019). Effect on 3LL and PC3 tumor cell viability (adapted from [98]). ND: not determined.
SpeciesPhylumIC50 vs. pAPA (µg/mL)IC50 vs. pAPN (µg/ML)IC50 vs. hAPN (µg/mL)IC50 vs. 3LL Viability (µg/mL)IC50 vs. PC3 Viability (µg/mL)
Cenchritis muricatusMolluscaNDND450.20 ± 77.40214.00 ± 46.50352.90 ± 65.00
Nerita pelorontaMollusca487 ± 11.03287.03 ± 12.00237.80 ± 20.90273.30 ± 78.80299.10 ± 31.70
Nerita versicolorMollusca92.23 ± 12.34132.11 ± 22.05370.00 ± 50.00358.80 ± 70.20289.70 ± 39.70
Lissodendoryx (Lissodendoryx) isodictyalisPorifera659.87 ± 10.65613.24 ± 10.7611.70 ± 2.70<5.00<5.00
Tripneustes ventricosusEchinodermata11.03 ± 0.1213.35 ± 3.9125.00 ± 3.1039.90 ± 2.0077.00 ± 3.90
Echinaster (Othilia) echinophorusEchinodermata182.01 ± 67.12112.55 ± 23.21198.20 ± 27.20265.70 ± 29.60405.60 ± 50.40
Isostichopus badionotusEchinodermata1005.12 ± 293.3211.08 ± 0.2769.70 ± 10.0057.10 ± 2.7083.10 ± 3.00
Stichodactyla helianthusCnidaria256.3 ± 10.00136.56 ± 22.87103.60 ± 20.60110.80 ± 13.2058.10 ± 7.50
Bunodosoma granuliferumCnidariaND98.02 ± 18.05567.60 ± 88.00786.80 ± 37.10711.30 ± 29.30
Physalia physalisCnidariaND198.92 ± 10.76123.10 ± 21.30257.30 ± 6.70234.50 ± 5.00
Bestatin (positive control)-25.50 ± 2.356.54 ± 0.826.70 ± 1.900.54 ± 0.013.15 ± 0.72
Amastatin (positive control)-75.45 ± 4.5558.32 ± 3.3463.45 ± 7.61NDND
Table
Table 7. Some members of the M17 family of the MF clan of metallopeptidases. (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 11 January 2023).
Table 7. Some members of the M17 family of the MF clan of metallopeptidases. (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 11 January 2023).
EnzymeIUBMB *
Nomenclature		Merops IDSources
Leucyl aminopeptidase 33.4.11.1M17.001Homo sapiens, Haemaphysalis longicornis, Mus musculus
Leucyl aminopeptidase (plant-type)3.4.11.1M17.002Solanum lycopersicum
PepA aminopeptidase3.4.11.10M17.003Escherichia coli, Pseudomonas aeruginosa
PepB aminopeptidase3.4.11.23M17.004Escherichia coli, Salmonella typhimurium
Mername-AA040 peptidase-M17.005Homo sapiens
Leucyl aminopeptidase-1 (Caenorhabditis-type)-M17.006Caenorhabditis elegans
M17 aminopeptidase (Plasmodium spp.)3.4.11.1M17.008Plasmodium spp.
Aminopeptidase yspII (Schizosaccharomyces sp.)-M17.009Schizosaccharomyces sp.
Leucyl aminopeptidase (Bacillus-type)-M17.010Geobacillus kaustophilus
Leucyl aminopeptidase (Fasciola-type)-M17.011Fasciola hepática
PwLAP aminopeptidase-M17.012Paragonimus westermani
Cysteinylglycinase (Treponema denticola)-like peptidase-M17.013Treponema denticola
LAPTc aminopeptidase-M17.014Trypanosoma cruzi, Leishmania major
Aminopeptidase pepZ (Staphylococcus sp.)-M17.015Staphylococcus aureus
Aminopeptidase A/I (Helicobacter-type)-M17.016Helicobacter pylori
similar to cytosol aminopeptidase (Rattus norvegicus)-M17.950Rattus norvegicus
At4g30920 (Arabidopsis thaliana)-M17.A01Arabidopsis thaliana
At4g30910 (Arabidopsis thaliana)-M17.A02Arabidopsis thaliana
At2g24200 (Arabidopsis thaliana)-M17.A03Arabidopsis thaliana
CG7340 g.p. (Drosophila melanogaster)-M17.A04Drosophila melanogaster
ZK353.6 (Caenorhabditis elegans)-M17.A05Caenorhabditis elegans
* IUBMB: International Union of Biochemistry and Molecular Biology.
Table
Table 8. Crystallographic structures reported for members of the M17 family of metallopeptidases (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 11 January 2023).
Table 8. Crystallographic structures reported for members of the M17 family of metallopeptidases (Compiled from https://www.ebi.ac.uk/merops/cgi-bin/, accessed on 11 January 2023).
EnzymeSourceCrystallographic Codes of the Structures at Protein Data Bank (PDB)
Leucyl aminopeptidase 3Bos taurus1BLL, 1BPM, 1BPN, 1LAM, 1LAN, 1LAP, 1LCP, 2EWB, 2J9A
Leucyl aminopeptidase (plant-type)Solanum lycopersicum4KSI, 5D8N
PepA aminopeptidaseEscherichia coli1GYT
Francisella tularensis3PEI
Pseudomonas putida3H8E, 3H8F, 3H8G
Xanthomonas oryzae3JRU
PepB aminopeptidaseEscherichia coli6OV8
Yersinia pestis6CXD
M17 aminopeptidase (Plasmodium spp.)Plasmodium falciparum3KQX, 3KQZ, 3KR4, 3KR5, 3T8W, 4K3N, 4R6T, 4R7M, 4X2T
LAPTc aminopeptidaseLeishmania major5NTH
Trypanosoma brucei5NSK, 5NSM, 5NSQ, 5NTD
Aminopeptidase A/I (Helicobacter-type)Helicobacter pylori4ZI6, 4ZLA
ZK353.6 (Caenorhabditis elegans)Caenorhabditis elegans2HB6, 2HC9
Table
Table 9. Summary of the screening of inhibitory activity against malarial rPfA-M17 and hLAP in aqueous extracts from marine invertebrates from the Cuban coastline (see note below). (adapted from Pascual et al. [98]).
Table 9. Summary of the screening of inhibitory activity against malarial rPfA-M17 and hLAP in aqueous extracts from marine invertebrates from the Cuban coastline (see note below). (adapted from Pascual et al. [98]).
SpeciesPhylaCrude Extract rPfA-M17
sIA (U/mg)		Crude Extract hLAP sIA (U/mg)2.5% TCA Treated Extracts rPfA-M17 sIA (U/mg)2.5% TCA Treated Extracts hLAP sIA (U/mg)
Cenchritis muricatusMollusca0.400.167.564.30
Nerita pelorontaMolluscaNDND10.616.48
Nerita versicolorMolluscaNDND7.175.58
Lissodendoryx (Lissodendoryx) isodictyalisPoriferaND0.27256.13312.01
Tripneustes ventricosusEquinodermataNDND41.8543.31
Echinaster (Othilia) echinophorusEquinodermata0.11ND9.107.85
Isostichopus badionotusEquinodermata0.181.2455.8327.86
Stichodactyla helianthusCnidaria0.550.6838.1518.67
Bunodosoma granuliferumCnidaria0.19ND5.454.08
Physalia physalisCnidaria0.40ND19.2111.00
NOTE: Inhibitory activities found in aqueous crude and 2.5% TCA extracts are expressed as specific Inhibitory Activity (sIA) in U/mg. One unit of enzyme activity was defined as the amount of enzyme needed to produce one arbitrary unit of fluorescence (AUF) per minute, and inhibitory activities are expressed per mg of extracts. The first column indicates the species, and the remaining columns refer to specific sIA. (ND): not detected.
Table
Table 10. Summary of the IC50 determination for the 2.5% TCA clarified extracts against rPfA-M17 and hLAP. Preliminarndicates position with high degree of conservation of the resy inhibitory analyses on the growth of Plasmodium falciparum FcB1 strain are included in the last column (adapted from Pascual et al. [98]).
Table 10. Summary of the IC50 determination for the 2.5% TCA clarified extracts against rPfA-M17 and hLAP. Preliminarndicates position with high degree of conservation of the resy inhibitory analyses on the growth of Plasmodium falciparum FcB1 strain are included in the last column (adapted from Pascual et al. [98]).
SpeciesIC50 Value vs. rPfA-M17 (µg/mL)IC50 vs. hLAP (µg/mL)IC50hLAP/ IC50rPfA-M17IC50 Pf FcB1 (µg/mL)
Cenchritis muricatus113.40 ± 3.00341.00 ± 110.003.00>400
Nerita peloronta22.20 ± 2.70329.50 ± 100.0014.80291.80 ± 38.50
Nerita versicolor207.00 ± 30.6012 429.60 ± 633.0060.00325.50 ± 0.80
Lissodendoryx (Lissodendoryx) isodictyalis27.30 ± 9.4066.30 ± 27.602.422.60 ± 0.60
Tripneustes ventricosus84.80 ± 7.30607.70 ± 300.507.160.24 ± 0.01
Echinaster (Othilia) echinophorus127.50 ± 82.10308.70 ± 100.002.42201.60 ± 162.10
Isostichopus badionotus86.70 ± 32.60272.70 ± 63.503.13183.70 ± 155.70
Stichodactyla helianthus15.30 ± 6.20234.90 ± 34.6015.35>400
Bunodosoma granuliferum509.20 ± 100.901171.00 ± 92.102.29>400
Physalia physalis293.70 ± 100.00550.00 ± 85.001.87206.00 ± 84.00
Bestatin (positive control)0.15 ± 0.0211.83 ± 2.6178.861.14 ± 0.27
Amastatin (positive control)60.70 ± 19.84158.05 ± 28.442.60ND
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pascual Alonso, I.; Almeida García, F.; Valdés Tresanco, M.E.; Arrebola Sánchez, Y.; Ojeda del Sol, D.; Sánchez Ramírez, B.; Florent, I.; Schmitt, M.; Avilés, F.X. Marine Invertebrates: A Promissory Still Unexplored Source of Inhibitors of Biomedically Relevant Metallo Aminopeptidases Belonging to the M1 and M17 Families. Mar. Drugs 2023, 21, 279. https://doi.org/10.3390/md21050279

AMA Style

Pascual Alonso I, Almeida García F, Valdés Tresanco ME, Arrebola Sánchez Y, Ojeda del Sol D, Sánchez Ramírez B, Florent I, Schmitt M, Avilés FX. Marine Invertebrates: A Promissory Still Unexplored Source of Inhibitors of Biomedically Relevant Metallo Aminopeptidases Belonging to the M1 and M17 Families. Marine Drugs. 2023; 21(5):279. https://doi.org/10.3390/md21050279

Chicago/Turabian Style

Pascual Alonso, Isel, Fabiola Almeida García, Mario Ernesto Valdés Tresanco, Yarini Arrebola Sánchez, Daniel Ojeda del Sol, Belinda Sánchez Ramírez, Isabelle Florent, Marjorie Schmitt, and Francesc Xavier Avilés. 2023. "Marine Invertebrates: A Promissory Still Unexplored Source of Inhibitors of Biomedically Relevant Metallo Aminopeptidases Belonging to the M1 and M17 Families" Marine Drugs 21, no. 5: 279. https://doi.org/10.3390/md21050279

APA Style

Pascual Alonso, I., Almeida García, F., Valdés Tresanco, M. E., Arrebola Sánchez, Y., Ojeda del Sol, D., Sánchez Ramírez, B., Florent, I., Schmitt, M., & Avilés, F. X. (2023). Marine Invertebrates: A Promissory Still Unexplored Source of Inhibitors of Biomedically Relevant Metallo Aminopeptidases Belonging to the M1 and M17 Families. Marine Drugs, 21(5), 279. https://doi.org/10.3390/md21050279

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop